Purdue University

Purdue e-Pubs
Open Access Dissertations

Theses and Dissertations

12-2017

Modulation of BCR Signaling by the Induced Dimerization of
Receptor- Associated SYK
Mark L. Westbroek
Purdue University

Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations

Recommended Citation
Westbroek, Mark L., "Modulation of BCR Signaling by the Induced Dimerization of Receptor- Associated
SYK" (2017). Open Access Dissertations. 1659.
https://docs.lib.purdue.edu/open_access_dissertations/1659

This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries.
Please contact epubs@purdue.edu for additional information.

MODULATION OF BCR SIGNALING BY THE INDUCED
DIMERIZATION OF RECEPTOR-ASSOCIATED SYK
by
Mark L. Westbroek

A Dissertation
Submitted to the Faculty of Purdue University
In Partial Fulfillment of the Requirements for the degree of

Doctor of Philosophy

Department of Medicinal Chemistry & Molecular Pharmacology
West Lafayette, Indiana
December 2017

ii

THE PURDUE UNIVERSITY GRADUATE SCHOOL
STATEMENT OF COMMITTEE APPROVAL

Dr. Robert L. Geahlen, Chair
Department of Medicinal Chemistry and Molecular Pharmacology
Dr. Philip S. Low
Department of Chemistry
Dr. Emily C. Dykhuizen
Department of Medicinal Chemistry and Molecular Pharmacology
Dr. Laurie L. Parker
Department of Biochemistry, Molecular Biology, and Biophysics, University of
Minnesota

Approved by:
Dr. Jean-Christophe Rochet
Head of the Graduate Program

iii

To my wife and children

iv

ACKNOWLEDGMENTS

My achievements to date are not only due to persistence and hard work, but also to many
who have mentored and supported me along the way. While a comprehensive list of all who have
helped me may not be realistic, I wish to acknowledge and express appreciation to those who have
guided, taught, and supported me the most.
Although I performed the chemical syntheses myself, I would not have been able to do so
without the guidance of Irene Boutselis, Christine Marian, and Richard Borch. They were always
willing to answer my questions and teach me more about analytical techniques or give me advice
about new procedures or improving yield. Others who mentored me were Walter Wever, Angela
Wolf, and Jaimeen Majmudar. I learned invaluable lessons from associating with each of these
individuals, for which I will always be grateful. I also wish to express appreciation to Minervo
Pérez for teaching me how to use the peptide synthesizer, HPLC, and LC-MS to synthesize, purify,
and analyze peptides, respectively.
Likewise, many went out of their way to teach me biological/biochemical methods. Albert
Bowers and Tony Hazbun taught me molecular cloning methods. My fellow lab members Mariya
Krisenko, Wen-Horng Wang, Soumitra Ghosh, and Shana Hardy helped me learn various
techniques. They have also been good friends who encouraged and uplifted me.
I especially owe appreciation to my academic advisor, Robert Geahlen. His patient, handsoff approach was exactly what I needed. He has always been there to answer questions and give
me suggestions, but stayed back and let me work things out on my own whenever possible. It
would be impossible to quantify how much I have learned from him. My advisory committee,
consisting of Philip Low, Laurie Parker, and Emily Dykhuizen, has also provided invaluable
insight that has helped and guided me along the way.
Finally, I thank my family for their love and encouragement. My wife, Marie, has been a
listening ear, a support to lean on, and a source of encouragement and motivation. My children
have also given me motivation to keep going when I felt like a failure. Their loving faith in my
abilities has boosted my self-confidence. I sincerely hope that someday I can become the superhero they see in me.
To all who have helped or supported me along the way, mentioned or not, I give my most
sincere thanks.

v

TABLE OF CONTENTS

LIST OF TABLES....................................................................................................................... viii
LIST OF FIGURES ....................................................................................................................... ix
LIST OF ABBREVIATIONS........................................................................................................ xi
ABSTRACT ................................................................................................................................. xiii
INTRODUCTION ................................................................................................ 1
1.1

Chemical Biology ............................................................................................................... 1

1.1.1

Dimerization Strategies ............................................................................................... 1

1.1.2

E. coli Dihydrofolate Reductase-Trimethoprim System ............................................. 2

1.2

B Cell Function ................................................................................................................... 4

1.2.1

B cell Antigen Receptor Structure and Function ......................................................... 4

1.2.2

Differential Outcomes of BCR Engagement ............................................................... 6

1.3

SYK in Stress Granules ...................................................................................................... 7

1.3.1

Stress Granule Function, Formation and Composition................................................ 7

1.3.2

SGs are Cleared through Autophagy ........................................................................... 8

1.3.3

A Role for SYK in mRNA Metabolism ...................................................................... 8

1.3.4

Pathologies Associated with SYK and SGs................................................................. 9

1.3.5

Approach to Investigate Association of SYK with SGs.............................................. 9

References.................................................................................................................................. 10
MATERIALS AND METHODS........................................................................ 19
2.1

Plasmids, DNA Constructs, and Antibodies ..................................................................... 19

2.2

Cell Culture and DNA Transfection/Transduction ........................................................... 20

2.3

Mass Spectrometry Sample Preparation and Analysis ..................................................... 20

2.4

Western Blotting ............................................................................................................... 22

2.5

Immunofluorescence Microscopy..................................................................................... 23

2.6

TMP-Agarose Pull-Down Assay ...................................................................................... 23

2.7

Cell Fractionation.............................................................................................................. 24

2.8

NFAT- and NFκB-Luciferase Reporter Assays................................................................ 24

2.9

Intracellular Calcium Assay.............................................................................................. 24

2.10

ImageJ Analyses ............................................................................................................. 25

vi
2.11

Synthesis of TMP Coupled to Agarose Beads ............................................................... 26

2.12

Synthesis of TMP Dimer 6 ............................................................................................. 28

2.13

Synthesis of TMP-Peptides ............................................................................................ 28

2.14

Synthesis of TMP-Aryl Azides ...................................................................................... 29

2.15

Synthesis of TMP-azide for Click Reaction ................................................................... 33

2.16

Synthesis of Glycated TMP............................................................................................ 34

References.................................................................................................................................. 35
MODULATION OF BCR SIGNALING BY THE INDUCED DIMERIZATION
OF RECEPTOR-ASSOCIATED SYK......................................................................................... 37
3.1

Introduction ....................................................................................................................... 37

3.2

Results............................................................................................................................... 38

3.2.1

eDHFR-tagged SYK Binds TMP .............................................................................. 38

3.2.2

TMP Dimer Induces SYK Aggregation .................................................................... 41

3.2.2.1 SYK Localizes to Stress Granules (SGs) ............................................................. 42
3.2.2.2 SYK Dimerization Induced by TMP Dimer Modulates SG Size ......................... 42
3.2.2.3 SYK Activity is not Required for TMP Dimer-induced Increase in SG Size ...... 44
3.2.2.3.1 MS analysis of MCF7-BD cells treated with SA ............................................ 45
3.2.2.3.2 Treatment of cells with SA results in a unique SYK-dependent phosphorylation
profile……........................................................................................................................ 57
3.2.3

Dimerized SYK Signals through NFAT or NFκB when Interacting with the BCR.. 63

3.2.4

TMP Dimer-induced SYK Activation Requires Association with the BCR ............. 65

3.2.5

Dimerization of SYK Promotes Sustained Ca2+ Mobilization .................................. 70

3.2.6

Retention of the BCR at the Plasma Membrane Enhances Signaling through NFAT 71

3.3

Discussion ......................................................................................................................... 73

References.................................................................................................................................. 76
FUTURE DIRECTIONS .................................................................................... 81
4.1

Introduction ....................................................................................................................... 81

4.2

Optimized TMP Dimer Synthesis..................................................................................... 81

4.3 TMP Pull-down Methods.................................................................................................. 83
4.3.1

Water-Soluble TMP for Protein Elution .................................................................... 83

4.3.2

Disulfide Linker for Protein Elution.......................................................................... 84

vii
4.3.3

Magnetic Pull-down Beads ........................................................................................ 84

4.3.3.1 Stable Cell Selection............................................................................................. 85
4.4

TMP-Aryl Azide Fingerprint Assay ................................................................................. 86

4.5

Subcellular Translocation Assay....................................................................................... 88

4.6

Conclusion ........................................................................................................................ 89

References.................................................................................................................................. 90
VITA ............................................................................................................................................. 94

viii

LIST OF TABLES

Table 1.1. List of chemical inducers of heterodimerization, including affinity tags (targets) and
synthetic ligands............................................................................................................ 2
Table 3.1. List of proteins phosphorylated in a SA- and SYK-dependent manner. ..................... 48
Table 3.2. List of proteins phosphorylated in MCF7-BD cells expressing SYK-EGFP when treated
with PV......................................................................................................................... 52
Table 3.3. GO term analysis of proteins phosphorylated in a SA- and SYK-dependent manner. 59
Table 3.4. GO term analysis of phosphoproteins from cells treated with PV. ............................. 60
Table 3.5. List of SG and P-body components phosphorylated in a SYK-dependent manner..... 62

ix

LIST OF FIGURES

Figure 1.1. The eDHFR-TMP chemical genetics system. .............................................................. 3
Figure 1.2. Schematic of SYK ........................................................................................................ 5
Figure 2.1. Reaction scheme for the preparation of TMP covalently coupled to agarose beads.. 26
Figure 2.2. Reaction scheme for the preparation of a TMP dimer. .............................................. 28
Figure 2.3. Reaction scheme for preparation of TMP-aryl azide 10 ............................................ 30
Figure 2.4. Reaction scheme for coupling TMP to a nitro-substituted aryl azide. ....................... 31
Figure 2.5. Reaction scheme for alkylation of 1 with a flexible linker terminating in an azide... 33
Figure 2.6. Reaction scheme for the preparation of a carbohydrate-substituted TMP analog...... 34
Figure 3.1. eDHFR-linked fusion proteins are stable. .................................................................. 39
Figure 3.2. Chemical structure of TMP covalently bound to agarose beads. ............................... 40
Figure 3.3. eDHFR-tagged proteins bind TMP. ........................................................................... 41
Figure 3.4. Chemical structure of TMP dimer. ............................................................................. 42
Figure 3.5. The size of cellular ribonuclear protein aggregates increased when SYK and TMP
dimerizing agent were present................................................................................... 43
Figure 3.6. SYK-EGFP-eDHFR is inactive.................................................................................. 44
Figure 3.7. Stresses that induce SG formation result in redistribution of SYK to detergent-insoluble
fraction. ....................................................................................................................... 45
Figure 3.8. PV induces general tyrosine phosphorylation, while SA induces localized tyrosine
phosphorylation. ........................................................................................................ 47
Figure 3.9. Venn diagram showing number of unique vs. duplicate phosphoproteins identified by
MS from cells treated with PV or SA. ........................................................................ 58
Figure 3.10. The TMP dimer enhances BCR-dependent activation of NFAT, but not NFκB. .... 64
Figure 3.11. The LYN N-terminal (NLyn) sequence. .................................................................. 66
Figure 3.12. NLyn-tagged SYK is localized to the plasma membrane. ....................................... 67
Figure 3.13. Dimerization of membrane-associated SYK is not sufficient to activate transcription
factors....................................................................................................................... 68
Figure 3.14. Enhanced NFAT activation by the TMP dimer requires the eDHFR affinity tag.... 69
Figure 3.15. Enhanced NFAT activation requires binding of TMP dimer to eDHFR-tagged SYK.70
Figure 3.16. The TMP dimer enhances the duration of calcium mobilization. ............................ 71

x
Figure 3.17. The TMP dimer increases the retention of SYK-BCR complexes. .......................... 72
Figure 3.18. Retention of BCR complex at the plasma membrane enhances NFAT signaling.... 73
Figure 4.1. TMP dimer linked with 1,6-hexanediamine in place of diethylenetriamine. ............. 82
Figure 4.2. Click reaction with TMP analog 15 and 1,8-nonadiyne to generate a TMP dimer.... 82
Figure 4.3. Chemical structure of glycated TMP.......................................................................... 83
Figure 4.4. Selective cleavage of TMP from agarose beads by reducing disulfide bond............. 84
Figure 4.5. Hypothetical eDHFR pull-down vector...................................................................... 86
Figure 4.6. Chemical structures of two TMP-aryl azide analogs. ................................................ 87

xi

LIST OF ABBREVIATIONS

ACN

Acetonitrile

BCR

B cell antigen receptor

BTK

Bruton’s tyrosine kinase

DAG

Diacylglycerol

DCM

Dichloromethane

DHFR

Dihydrofolate reductase

DMF

N,N-Dimethylformamide

DMSO

Dimethylsulfoxide

eDHFR

E. coli dihydrofolate reductase

EGFP

Enhanced green fluorescent protein

eIF2α

Elongation initiation factor 2 α

EtOAc

Ethyl acetate

FKBP12

FK506 binding protein 12

FRB

FK506 rapamycin binding domain

G3BP

Ras-GAP SH3 domain binding protein

GAPDH

Glyceraldehyde 3-phosphate dehydrogenase

GRB7

Growth factor receptor-bound protein 7

GyrB

Bacterial DNA gyrase B subunit

IκB

Inhibitor of NFκB

IKK

IκB kinase

IP3

Inositol 1,4,5-trisphosphate

ITAM

Immunoreceptor tyrosine-based activation motif

LatB

Latrunculin B

xii
LC

Liquid chromatography

MeOH

Methanol

MS

Mass spectroscopy

MTX

Methotrexate

NFAT

Nuclear factor of activated T cells

NFκB

Nuclear factor kappa-light-chain-enhancer of activated B cells

NLyn

N-terminal LYN membrane-targeting sequence

P-body

mRNA processing body

PIP2

Phosphatidylinositol 4,5-bisphosphate

PKCβ

Protein kinase C β

PLCγ2

Phospholipase C γ 2

PV

Sodium pervanadate

SA

Sodium arsenite

SG

Stress granule

SH2

SRC-homology 2 domain

SLF

Synthetic ligand of FKBP12

SYK

Spleen tyrosine kinase

TFA

Trifluoroacetic acid

TIA-1

T cell intracellular antigen 1

TIAR

TIA-1 related protein

TMP

Trimethoprim

VCP

Valosin-containing protein

xiii

ABSTRACT

Author: Westbroek, Mark L. PhD
Institution: Purdue University
Degree Received: December 2017
Title: Modulation of BCR Signaling by the Induced Dimerization of Receptor-Associated SYK.
Major Professor: Robert Geahlen
Clustering of the B cell antigen receptor (BCR) by polyvalent antigens is transmitted
through the SYK tyrosine kinase to the activation of multiple intracellular pathways that determine
the physiological consequences of receptor engagement. To explore factors that modulate the
quantity and quality of signals sent by the crosslinked BCR, I developed a novel chemical mediator
of dimerization to induce clustering of receptor-associated SYK. To accomplish this, I fused SYK
with E. coli dihydrofolate reductase (eDHFR), which binds the small molecule trimethoprim (TMP)
with high affinity and selectivity, and synthesized a dimer of TMP with a flexible linker. The
binding of TMP derivatives to eDHFR containing fusion proteins was verified by affinity capture
chromatography using a resin containing immobilized TMP. The TMP dimer is able to induce the
aggregation of eDHFR-linked SYK in live cells, as evidenced by an increase in size of SYKassociated stress granules (SGs). As determined by a mass spectrometric analysis, the sodium
arsenite-induced association of SYK with SGs induces a unique SYK-dependent tyrosine
phosphorylation profile as compared to cells treated with the tyrosine phosphatase inhibitor,
pervanadate, which does not induce SG formation. SYK tagged with eDHFR is able to support
BCR signaling in SYK-deficient B cells. The induced dimerization of SYK bound to the BCR
differentially regulates the activation of downstream transcription factors, promoting the activation
of NFAT without affecting the activation of NFB. This effect requires the association of SYK
with the receptor as cytoplasmic or membrane-targeted SYK fusion proteins do not signal
following dimerization in the absence of BCR crosslinking. The dimerization of SYK enhances
the duration, but not the amplitude of calcium mobilization by enhancing the extent and duration
of its interaction with the crosslinked BCR at the plasma membrane. These results are consistent
with a model whereby interactions between neighboring SYK-BCR complexes during aggregation
promote the retention of these kinase-receptor complexes at the membrane leading to prolonged
calcium mobilization and increased NFAT activation.
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INTRODUCTION

1.1

Chemical Biology

Chemical genetics is a growing field of science that combines molecular biology with
chemistry. It seeks to use genetic approaches to increase specificity, while also using chemistry to
increase the reaction speed. This involves creating orthogonal small molecules that bind
specifically to engineered proteins, and allows the dynamic exploration of protein properties that
would be difficult to examine otherwise.1
Considering these advantages, I synthesized various chemical probes that I have used with
cells to study macromolecular complexes and signaling. Most notably among these probes is one
that modulates protein aggregation by chemically inducing dimerization.
1.1.1

Dimerization Strategies
The first method developed to induce dimerization in live cells took advantage of the high

affinity interaction of the immunosuppressive drug FK506 with FK506 binding protein 12
(FKBP12). Spencer, et al.2 developed this system by synthesizing a dimer of FK506 (called
FK1012) and tagging the ζ chain of the T cell antigen receptor with FKBP12. They demonstrated
that by manipulating the extent of receptor crosslinking with FK1012, they could alter signaling.2
Synthetic optimization of FK1012 led to the development of a synthetic ligand of FKBP12 (SLF)
that binds preferentially to FKBP12 F36V.3-6 However, although SLF binds FKBP12 F36V with
extremely high affinity (Kd = 94 pM), it still binds WT FKBP with fairly high affinity (K d = 67
nM).4 Farrar, et al.7, 8 developed an additional method to chemically induce homodimerization
with the natural product coumermycin. Coumermycin had previously been characterized as a
coumarin dimer, and had been shown to simultaneously bind two bacterial DNA gyrase B (GyrB)
protein monomers.9 Farrar, et al. tagged RAF-1 with GyrB, and showed that dimerization induced
by coumermycin resulted in activation of the downstream MAPK kinase cascade.7 Finally, Carlson,
et al.10 developed a dimer of the dihydrofolate reductase (DHFR) inhibitor methotrexate (MTX)
and demonstrated crystallographically that it induced dimerization of purified DHFR. They then
used this system to highlight important considerations in the rational design of protein
dimerizers.10
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Others also have introduced reagents for the formation of heterodimers. One approach took
advantage of the unique binding properties of the small molecule rapamycin.5, 11, 12 Rapamycin
simultaneously binds both FKBP12 and the FKBP rapamycin binding (FRB) domain of mTOR.13
Using FKBP12 and FRB as affinity tags for two proteins of interest, this system can be used to
induce heterodimerization. Alternatively, one affinity tag can be fused with a localization sequence,
and this system can provide a means to translocate a protein of interest to a specific subcellular
compartment.5, 11, 12 Additional methods were also developed that utilized plant hormones that
induce heterodimerization of binding proteins, similar to rapamycin.11 Other systems also have
been developed to induce heterodimerization by synthesizing ligands that bind two different
affinity tags (Table 1.1).

Table 1.1. List of chemical inducers of heterodimerization, including affinity tags (targets) and
synthetic ligands.
Target 1
FKBP12
FKBP12
HaloTag
E. coli DHFR
E. coli DHFR
DHFR
E. coli DHFR

Target 2
Calcineurin A
Cyclophilin
SNAP-Tag
FKBP12 F36V
HaloTag
Glucocorticoid Receptor
Glucocorticoid Receptor

Ligand
FK50614
FKCsA15
HaXS16
TMP-SLF17
cTMP-Htag18
MTX-DEX19
TMP-DEX20

Although these systems have proven to be effective in certain circumstances, I sought to
develop a new system that did not require expression of more than one affinity tag or of a tag that
is also an endogenously expressed protein. I also noted that coumermycin is relatively inflexible,
and FK1012 and SLF dimers harbor small flexible linkers. This presents the possibility of reducing
interactions after dimerization due to steric hindrance. Therefore, I designed a system in which
proteins could be selectively aggregated by a dimerizer containing a long, flexible linker.
1.1.2

E. coli Dihydrofolate Reductase-Trimethoprim System
Escherichia coli DHFR (eDHFR) has recently received great attention as an affinity tag

due to its small size (~18 kDa) and its high affinity interaction with the small molecule
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trimethoprim (TMP), shown in Figure 1.1.A. TMP is a competitive inhibitor of eDHFR that binds
with very high affinity (Kd = 9.1 nM)21 and selectivity (it binds eDHFR with >10,000× higher
affinity than mammalian DHFR).22 Research has also shown that the 4’-methoxy moiety of the
benzyl group faces the exterior of the binding pocket, allowing it to be modified without
significantly affecting its binding to eDHFR.23, 24 This allows for a protein of interest to be tagged
with eDHFR, while TMP is chemically modified to function as a probe for molecular biology
studies. Additionally, because of the binding characteristics of TMP, these probes essentially only
react with the protein of interest, with very high affinity. For example, this method has been used
to label proteins with fluorescent probes, including fluorescein, BODIPY Texas red,25 and
hexachlorofluorescein,26 as well as specialized dyes for two-photon imaging27 and superresolution microscopy.28 By modifying these methods, I have synthesized various TMP derivatives
and used eDHFR as an affinity tag to study SYK protein tyrosine kinase function in B cells (Figure
1.1.B).
Although previous methods have used the DHFR inhibitor MTX to induce dimerization,10
I selected TMP because of its greater selectivity. MTX has been reported to inhibit DHFR from
multiple organisms, including bacterial, yeast, and human DHFR. Clinical studies have even
shown some success in treating human cancers with MTX.20, 29 Therefore, by employing TMP
instead of MTX, I was able to avoid potential interactions with endogenous proteins.

Figure 1.1. The eDHFR-TMP chemical genetics system. A. Chemical structure of TMP. B.
eDHFR-TMP Model - the protein of interest is fused to E. coli dihydrofolate reductase (eDHFR),
and a tagged analog of trimethoprim (TMP) is added to the cells.
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1.2

B Cell Function

B lymphocytes are an integral part of the adaptive immune response. Their primary function
is to produce antibodies.30 Among their many protective features, antibodies serve to opsonize
pathogens for phagocytosis, neutralize toxins, and sensitize cancerous or infected cells for attack
by natural killer cells.30 Defects in B cells, inherited or acquired, result in immunodeficiencies due
to the inability to produce sufficient quantities of antibodies.31, 32
B cells develop in the bone marrow, where they produce antigen-specific receptors by
random DNA rearrangements.30, 33 Before exiting the bone marrow, B cells undergo a negative
selection process to prevent self-reactive cells from entering the circulation. Studies in transgenic
mice have shown that when immature B cells in the bone marrow bind self antigen, they undergo
developmental arrest, followed by apoptosis.34 However, occasionally self-reactive cells do escape
into circulation. Here, however, exposure to antigen typically leads to anergy, or nonresponsiveness.35 This feature normally functions to protect against development of autoimmune
disorders.33
1.2.1

B cell Antigen Receptor Structure and Function
The B cell antigen receptor (BCR) of a mature B lymphocyte consists of a membrane-

bound immunoglobulin of the IgM or IgD class, together with the heterodimeric co-receptor
proteins CD79A (Igα) and CD79B (Igβ).36 Both Igα and Igβ contain two conserved tyrosine
residues on their cytoplasmic tails that constitute an immunoreceptor tyrosine-based activation
motif (ITAM).37 Binding of antigen results in aggregation of multiple BCR complexes, which
initiates signal transduction.36 BCR crosslinking promotes phosphorylation of ITAM tyrosines,
primarily by SRC-family kinase LYN, which recruits signaling proteins containing SRChomology 2 (SH2) domains.37,

38

Phosphorylation of both ITAM tyrosines is required for

recruitment of SYK.39
SYK is a 72 kDa non-receptor tyrosine kinase. Its structure consists of two N-terminal SH2
domains, separated from each other by a linker A region, and a C-terminal catalytic domain. The
catalytic domain is separated from the SH2 domains by a linker B region (see Figure 1.2).36
Binding of the SH2 domains to doubly phosphorylated ITAMs confers a conformational change
that activates SYK and allows it to phosphorylate downstream signaling proteins.40 Takata, et al.41
first demonstrated the requirement of SYK for propagation of BCR signaling by generating LYN-
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and SYK-deficient DT40 chicken B cell lines. They demonstrated that LYN-deficient cells
exhibited delayed signaling, but SYK-deficient cells were incapable of signaling through the BCR.
Later, several groups reported that SYK deletion in mice resulted in perinatal lethality.42,

43

Additionally, hematopoietic stem cells isolated from these SYK-deficient fetuses were unable to
differentiate into mature B cells when grafted into lethally irradiated recipient mice, thus
demonstrating the dependence of B cell development on SYK activity.42, 43

Figure 1.2. Schematic of SYK
One of the primary ways that SYK couples the BCR to downstream signaling pathways is
by phosphorylation of the adapter protein B cell linker (BLNK).44 Phospho-BLNK serves as a
docking site for SH2 domain-containing proteins such as the guanine nucleotide exchange factor
VAV, phospholipase C γ2 (PLCγ2) and Bruton’s tyrosine kinase (BTK).44-47 Association of VAV
with BLNK and Grb2/SOS localizes VAV to lipid rafts, where it is able to activate the RHO family
GTPase RAC1 and initiate signaling through extracellular signal-regulated kinase (ERK), p38
mitogen-activated protein kinase (p38 MAPK), and c-Jun N-terminal kinase (JNK).47, 48 Binding
of BTK and PLCγ2 to phospho-BLNK allows BTK to phosphorylate and activate PLCγ2.45, 49 The
activated PLCγ2 cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol 1,4,5trisphosphate (IP3) and diacylglycerol (DAG).37 The IP3 then binds to IP3 receptors on the
endoplasmic reticulum, resulting in Ca2+ release from internal stores. This then triggers Ca2+ influx
from the extracellular environment.50
Ca2+ signaling is essential for the activation of two key transcription factors: nuclear factor
kappa-light-chain-enhancer of activated B cells (NFκB) and nuclear factor of activated T cells
(NFAT).51 Under resting conditions, NFκB is excluded from the nucleus, and thus inactivated, by
association with inhibitor of NFκB (IκB).52, 53 DAG and free Ca2+ cooperatively activate protein
kinase C β (PKCβ), which is coupled through CARMA1, BCL10 and MALT1 to the activation of
transforming growth factor beta-activated kinase 1 (TAK1) and the phosphorylation of IκB kinase
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(IKK).54-56 IKK phosphorylates IκB, which targets it for ubiquitylation and proteasomal
degradation.53,

57, 58

This allows NFκB to translocate into the nucleus to participate in

transcriptional regulation.52, 53 NFAT also is excluded from the nucleus in resting cells, but by a
nuclear localization sequence that is masked by phosphorylation.59,

60

Free Ca2+ activates

calcineurin, a serine/threonine phosphatase that dephosphorylates NFAT. Dephosphorylation
allows NFAT to translocate from the cytoplasm to the nucleus to regulate transcription.59,

60

Interestingly, Dolmetsch, et al.51 determined that different durations and amplitudes of Ca2+
signaling are required to activate NFκB and NFAT. They used timed measurements of intracellular
Ca2+ concentration [Ca2+]i to show that NFκB is activated by brief, large pulses of Ca2+, while
NFAT activation requires low, sustained Ca2+ mobilization.51
1.2.2

Differential Outcomes of BCR Engagement
The extent of activation of NFAT and NFκB largely decides the ultimate response of the

cell to the external stimulus, as they activate different signals. Chronic activation of NFAT,
resulting from low, sustained Ca2+ mobilization, and low NFκB activity results in anergy, or nonresponsiveness.61 Conversely, NFκB activation has been associated with antibody production,
survival, and proliferation.62-64 However, both NFAT and NFκB are required for full B cell
activation.37 How such drastically different responses can result from signaling through the same
receptor components is not well understood, but is worth great consideration.
Some evidence suggests that the length of receptor occupancy affects the signal and the
ultimate physiological response of a B cell to antigen. Guald, et al.35 demonstrated this by using
several transgenic mouse models of anergy. The B cells of these mice expressed receptors that
recognized both a polyvalent, expressed hapten and a monovalent, soluble hapten. By measuring
[Ca2+]i, they showed that B cells were anergic when chronically exposed to polyvalent antigen, but
became responsive when excess monovalent antigen (incapable of crosslinking the BCR)
competed for binding.35 This suggests that chronic receptor occupancy induces anergy.
Evidence also exists that SYK may alter BCR residence at the plasma membrane. Ma, et
al.65 demonstrated that expression of SYK in DT40 cells significantly increased the length of time
the engaged BCR was retained at the plasma membrane. To accomplish this, they compared SYKdeficient DT40 cells to cells expressing SYK-GFP. After treating the cells with anti-IgM to
crosslink the BCR, they showed that the BCR of SYK-deficient cells was rapidly internalized. On
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the contrary, when SYK was present, a significant quantity of BCR complexes were still localized
at the plasma membrane after one hour.65 Later, Oh, et al.66 used an analog-sensitive construct of
SYK, SYK-AQL-GFP, to demonstrate that SYK’s activity was required to maintain the BCR at
the plasma membrane. By adding an orthogonal inhibitor, they demonstrated that inhibition of
SYK resulted in rapid internalization of the BCR complex.66 The current theory is that SYK
promotes retention of the BCR at the plasma membrane by keeping the receptor phosphorylated.
Thus, the more clustering that occurs, the more SYK is able to phosphorylate neighboring
complexes to prolong signaling.36 This is important as it is the kinase-BCR complexes that remain
at the plasma membrane that represent the units that are actively signaling. 67 However, it is
unknown how SYK contributes to the differential physiological responses of the cell. Does
promoting BCR retention at the plasma membrane mimic chronic receptor occupancy and induce
anergy, or does it simply magnify the signal to induce B cell activation?
To address this question, I used a chemical genetics approach to manipulate SYK-BCR
crosslinking by fusing SYK with eDHFR. I then synthesized a dimer of TMP to chemically induce
the dimerization of SYK to study its effects on BCR signaling. The goal was to develop an
approach through which SYK-SYK interactions could be induced once the kinase had associated
with the BCR complex to determine how this might affect receptor coupling to the activation of
downstream transcription factors.

1.3
1.3.1

SYK in Stress Granules

Stress Granule Function, Formation and Composition
Another macromolecular complex that SYK associates with is stress granules (SGs). SGs

are large aggregates of protein and mRNA that form in response to stresses that stall mRNA
translation initiation, such as heat shock, glucose depravation, oxidative stress, proteasome
inhibition, viral infection, or exposure to arsenite.68, 69 These types of stresses typically result in
the phosphorylation of elongation initiation factor 2 α (eIF2α), which ultimately inhibits translation
initiation.70, 71 The RNA-binding proteins T cell intracellular antigen 1 (TIA-1), TIA-1 related
protein (TIAR), and Ras-GAP SH3 domain binding protein (G3BP) then promote aggregation of
SG components along with the stalled translation initiation complex.70, 72 SGs are thought to
sequester mRNA from degradation until the stress is relieved.68, 69 They also have been shown to
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sequester pro-apoptotic proteins such as TRAF2 to promote cell survival.73 Stress granules lack a
membrane and components undergo liquid-liquid phase separation to form protein-rich droplets
that are irregular in size and can undergo fusion and fission.74, 75 SGs are dynamic, and mRNAs
are able to cycle between SGs, polysomes, and mRNA processing bodies to regulate translation
and mRNA decay.76, 77
1.3.2

SGs are Cleared through Autophagy
Autophagy is a “self-eating” process where cells catabolize macromolecules and/or

organelles to generate metabolites for energy production, and is often used during stress to avoid
cell death.78, 79 The process requires the macromolecule or organelle to be surrounded by a double
membrane vesicle, called an autophagosome, which then fuses with the lysosome for
degradation.78, 79 Several studies have demonstrated that, after stress removal, SGs are cleared by
autophagy.80-82 Buchan, et al.80 used a yeast library of non-essential gene deletions to identify 125
genes involved in SG dynamics. Among these, they demonstrated that gene deletions disturbing
autophagy resulted in accumulation of SGs. Additionally, they determined that SGs were targeted
to the autophagosome by Cdc48, the yeast ortholog of valosin-containing protein (VCP).80 VCP is
a AAA+-ATPase chaperone-like protein that targets ubiquitylated proteins to the autophagosome.83
Buchan, et al. then confirmed that this process is conserved in mammalian cells.80
1.3.3

A Role for SYK in mRNA Metabolism
We previously performed mass spectrometric (MS) analyses comparing phosphorylation

in SYK-deficient MDA-MB-231 breast cancer cells to cells ectopically expressing SYK.84 After
treating the cells with sodium pervanadate, a tyrosine phosphatase inhibitor that also causes
oxidative stress, remarkable differences in phosphorylation were noted between SYK-deficient
and

SYK-expressing

cells.

Interestingly,

these

analyses

identified

SYK-dependent

phosphorylation of several SG components.84 This led to the hypothesis that SYK was a SGassociated protein.
We demonstrated using microscopy that SYK does, in fact, co-localize with SGs in a
variety of cell types, including breast cancer cells, B cell lymphoma, and microglial cells. 85, 86 In
breast cancer cells, the recruitment of SYK to SGs was dependent on the phosphorylation of Y342
and Y346 in the linker B region of the kinase. These phosphotyrosines interact with growth factor
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receptor-bound protein 7 (GRB7), an adapter protein and known SG component.86, 87 It was shown
by immunofluorescence that SYK is active in SGs, resulting in the SYK-dependent appearance of
tyrosine-phosphorylated proteins in SGs, and that SYK promotes SG clearance via autophagy upon
removal of the stress.86
1.3.4

Pathologies Associated with SYK and SGs
The recruitment of SYK to SGs can have pathological consequences in cells in which SYK

plays important roles in such processes as receptor-mediated activation and phagocytosis. Studies
in our laboratory using microglial cells demonstrated a potential pathological role for the SG-SYK
interaction in Alzheimer’s disease.85 Microglial cells are the main phagocytic cells of the central
nervous system. In Alzheimer’s disease, these cells show an activated phenotype, but diminished
activity.85 We demonstrated that chronic stress conditions mimicking Alzheimer’s disease induced
formation of massive SGs that could not be cleared by autophagy. These large SGs sequestered
SYK from the plasma membrane, rendering the cells incapable of phagocytosis, which is a SYKdependent process.85 Interestingly, SYK was still active while in these SGs, and promoted
generation of reactive oxygen and nitrogen species, which is characteristic of activated microglial
cells. Our studies suggest that SYK and SGs play an important function in the pathology of
Alzheimer’s disease.85 This is interesting as defects in SG clearance contribute to neurological
disorders, such as amyotrophic lateral sclerosis and frontotemporal dementia.88, 89
1.3.5

Approach to Investigate Association of SYK with SGs
The treatment of MDA-MB-231 cells with pervanadate does not promote an obvious

accumulation of SGs. This suggests that the treatment of another cell type such as MCF7 with a
reagent such as sodium arsenite that does result in robust SG formation, might represent a better
platform for confirming an interaction of active SYK with SGs and for identifying substrates that
it modifies within these particles. To further confirm an interaction of SYK with ribonucleoprotein
granules, we performed a phosphoproteomic analysis by MS to compare substrates phosphorylated
in response to pervanadate versus sodium arsenite. These analyses demonstrate a unique
phosphorylation pattern when SYK is localized to SGs and support an interaction between SYK
and SG components. Finally, we demonstrate that inducing aggregation of SYK while forming
SGs modulates the size of these dynamic structures.
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MATERIALS AND METHODS

2.1

Plasmids, DNA Constructs, and Antibodies

The SYK-EGFP construct was generated as previously described.1 SYK-EGFP and EGFP
were subcloned into the pLL-1 vector (Active Motif) to generate SYK-EGFP-eDHFR and EGFPeDHFR. SYK-EGFP and EGFP were PCR-amplified using the following primers: SYK forward
primer 5’ CAG GTA AGC TTG ATG GCG GGA AGT G, EGFP forward primer 5’ CCG CTA
GCA AGC TTG ATG GTG AGC AAG GGC G, and EGFP reverse primer 5’ GAG CCC TCG
AGC CTT GTA CAG CTC GT. The amplified constructs were then purified by agarose gel
purification kit (Qiagen). Purified constructs and pLL-1 plasmid were restriction digested with
HindIII/XhoI, the plasmid was treated with Antarctic Phosphatase (NEB), and the inserts were
ligated to the plasmid with Quick Ligase (NEB). These constructs were then further subcloned to
the pCDH-CMV-MCS-EF1-Puro lentiviral vector (System Biosciences) via the same method,
using SYK forward primer 5’ TAG AAG ATT CTA GAG CCA CCA TGG CGG GAA GTG CTG,
EGFP forward primer 5’ TTT AAA TCG GAT CCG GCC ACC ATG GTG AGC AAG GGC G,
and eDHFR reverse primer 5’ GAT CCT TCG CGG CCG CTT ACC GCC GCT CCA GA. SYKEGFP-eDHFR and EGFP-eDHFR constructs were digested with XbaI/NotI and BamHI/NotI
restriction enzymes, respectively.
The Myc-SYK construct was generated as previously described.2 Myc-SYK and Mycepitope tag were subcloned into the pLL-1 vector (Active Motif) to generate Myc-SYK-eDHFR
and Myc-eDHFR. Myc-SYK and Myc were PCR-amplified using the following primers: MycSYK forward primer 5’ CCG CTA GCA AGC TTG ATG GCA TCA ATG CAG AAG C, MycSYK reverse primer 5’ TGA GTA CTC TCG AGC GTT AAC CAC GTC GTA GTA GT, Myc
forward primer 5’ CGA ATT CGG TCG ACG ATG GTG GGT TCT GGT GG, and Myc reverse
primer 5’ GGA TCC CCG CGG CCG CTT ACC GCC GCT CCA GA. The amplified constructs
were purified and inserted as before using restriction enzymes HindIII/XhoI for Myc-SYK and
SalI/NotI for Myc. These constructs were then further subcloned to the pCDH-CMV-MCS-EF1Puro lentiviral vector (System Biosciences) using the following primers: Myc forward primer 5’
TTT AAA TCG GAT CCG GCC ACC ATG GCA TCA ATG CAG AAG C and eDHFR reverse
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primer 5’ GAT CCT TCG CGG CCG CTT ACC GCC GCT CCA GA. The restriction enzymes
BamHI/NotI were used for both constructs.
The following antibodies were used for Western blotting and/or immunofluorescence:
SYK (D3Z1E XP, Cell Signaling), GFP (B-2, Santa Cruz Biotechnology), G3BP (611126, BD
Biosciences), Myc (9B11, Cell Signaling), and GAPDH (AM4300, Ambion). HRP-coupled
secondary antibodies were purchased from Pierce, and Alexa Fluor 405-, 488-, and 594-coupled
secondary antibodies from Invitrogen.

2.2

Cell Culture and DNA Transfection/Transduction

HEK293T (ATCC) and SYK-deficient MCF7 cells (MCF7-BD)3 were cultured in DMEM
medium supplemented with 10% FBS, 0.37% NaHCO3, 100 IU/mL penicillin, and 100 μg/mL
streptomycin. SYK-deficient DT40 cells4 were cultured in RPMI 1640 medium supplemented with
10% FBS, 1% chicken serum, 50 μM 2-mercaptoethanol, 1 mM sodium pyruvate, 100 IU/mL
penicillin G, and 100 μg/mL streptomycin.
DT40 cells were transfected via electroporation. The cells were collected (1×107) and
resuspended in 500 μL cell culture medium and incubated with the respective plasmids at room
temperature for 5 min. Cells were electroporated at 250 V, 975 μF, and then incubated on ice for
10 min. Cells were recovered in 10 mL pre-warmed cell culture medium for 24-48 h.
To generate cells stably expressing SYK-EGFP-eDHFR, EGFP-eDHFR, Myc-SYKeDHFR, or Myc-eDHFR, lentiviral particles were packaged using HEK293T cells according to
manufacturer instructions. HEK293T, SYK-deficient DT40, and MCF7-BD cells were transduced
with the lentiviral particles, selected with puromycin (1 μg/mL), and screened for expression by
fluorescence microscopy and Western blotting.

2.3

Mass Spectrometry Sample Preparation and Analysis

MCF7-BD cells stably expressing SYK-GFP were treated with sodium pervanadate (5 mM
H2O2, 1 mM sodium orthovanadate) for 30 min at 37°C. Cells with or without SYK-GFP
expression were treated with sodium arsenite (500 μM) for 2 h at 37°C. After treatment, cells were
washed with cold PBS, pelleted, and briefly frozen at -80°C. Frozen cells were resuspended in
lysis buffer containing 100 mM Tris-HCl, 150 mM NaCl, 1% NP-40, sodium pervanadate, and
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phosphatase inhibitor cocktails 2 and 3 (Sigma). They were left on ice for 5 min before sonication
with a probe sonicator (3 times 5 s each). Cell debris was cleared by centrifugation at 1,000 × g.
The protein concentration of the supernatant was measured with a BCA assay (Thermo Scientific)
according to the manufacturer’s instructions. From each sample, 2 mg of protein was digested with
trypsin using a SMART Digest kit (Thermo Scientific) at a ratio of 30 μL resin:1 mg protein. After
addition of the resin, samples were incubated at 70°C for 90 min with rotation at 1200 rpm. After
digestion, the samples were treated with 10 mM DTT for 30 min at 50°C in the dark followed by
20 mM iodoacetamide for 1 h at room temperature in the dark. The samples were then acidified to
pH < 3 with 10% TFA, desalted with Sep-Paks (Waters), and dried to completion in a Speed Vac.
Dried samples were resuspended in 600 μL of 100 mM Tris-HCl, pH 8.0, and incubated
with phosphotyrosine antibodies conjugated to agarose beads (clone PT66, Sigma) at a ratio of 30
μL beads:1 mg starting protein for 12-16 h at 4 C. On the next day, the beads were washed twice
with cold lysis buffer for 10 min each at 4°C and twice with cold water. Phosphotyrosinecontaining peptides were eluted three times with 0.1% TFA and twice with 0.1% TFA in 50%
ACN. All elutions were done with 100 μL of buffer for 10 min at room temperature with vigorous
agitation. The eluted peptides were then dried to completion in a Speed Vac and stored at -80°C
until further use.
Immediately before LC-MS analysis, phosphopeptides were enriched using PolyMAC
(Tymora Analytical, West Lafayette, IN) according to the manufacturer’s instructions. The
samples were resuspended in 10 μL of 0.3% formic acid in 3% ACN, and 8 μL from each were
injected into an Easy nLC 1000 system (Thermo Scientific) coupled online to a LTQ-Orbitrap
Velos Pro mass spectrometer (Thermo Scientific). Peptides were separated on a linear gradient
over 90 min using mobile phases of 0.1% formic acid (A) and 0.1% formic acid in 80% ACN (B).
The ESI emitter tip was pulled in-house, and the 40 cm analytical column (360 μm OD, 75 μm ID)
was packed in-house using 2.2 μm ProntoPEARL C18 AQ beads (Bischoff Chromatography,
Leonberg, Germany). During the analysis, the column was maintained at 50°C with a column
heater (Analytical Sales and Services, Flanders, NJ). The mass spectrometer was operated in datadependent mode in which one full survey scan from 300 to 1600 m/z was followed by selection of
the 15 most abundant ions for MS/MS and fragmentation by collision-induced dissociation
(normalized collision energy 35%). The automatic gain control was set to 3e4 with a maximum
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injection time of 100 ms. Unassigned charge states and charge states of +1 were rejected for
MS/MS, and the dynamic exclusion time was set to 90 s.
Raw mass spectrometry data were analyzed using the SEQUEST node built into
ProteomeDiscoverer 2.1 (Thermo Scientific) with the Homo sapiens FASTA database (no
redundant entries; downloaded from Uniprot February 2016). Precursor mass tolerance was 10
ppm, and the fragment match tolerance was 0.6 Da. Search criteria included a static modification
of cysteine residues of +57.0214 Da to account for alkylation and a variable modification of
+15.9949 Da for potential oxidation of methionine residues. A variable phosphorylation
modification of +79.996 Da was also specified for serine, threonine, and tyrosine residues. False
discoveries were identified using a reverse decoy database, and the false discovery rate was set to
1%. Phosphorylation sites were localized using ptmRS algorithm.

2.4

Western Blotting

Cells were lysed in ice cold NP-40 lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 10%
glycerol, 1% NP-40, 1 mM sodium orthovanadate, protease inhibitor cocktail [Sigma, p8340]),
sonicated, and centrifuged at 17,000 × g for 5 min at 4°C. Supernatants were mixed 1:1 with 2x
SDS sample buffer (2.5% SDS, 2% 2-mercaptoethanol, 25% sucrose, 2.5 mM EDTA, 25 mM Tris,
pH 8, 2.5 mg% pyronin Y), heated for 5-10 min at 99°C, and separated by SDS-PAGE. Proteins
were then transferred to PVDF membranes in transfer buffer (25 mM Tris, 0.2 M glycine, 20%
MeOH). Membranes were blocked with 5% goat serum in NP-40 wash buffer (0.1% NP-40, 150
mM NaCl, 50 mM Tris, pH 7.5), then incubated with primary antibody in blocking buffer
overnight at 4°C. The membranes were washed with NP-40 wash buffer twice for 10 min, then
high salt buffer (500 mM NaCl, 20 mM Tris, pH 7.5) for 10 min. The membranes were then
incubated with secondary antibody in blocking buffer for 45 min at room temperature, washed
with NP-40 wash buffer twice for 10 min, and high salt buffer for 10 min. The membranes were
treated with SuperSignal® West Pico chemiluminescent HRP substrate (Thermo Scientific), and
the blots were developed on autoradiography film.
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2.5

Immunofluorescence Microscopy

MCF7-BD cells stably expressing SYK-EGFP-eDHFR, EGFP-eDHFR, Myc-SYKeDHFR or Myc-eDHFR were plated on coverslips in 6-well plates and treated with MG132 (100
μM, Selleck Chemicals) with or without TMP dimer for 6 h at 37°C and then immunostained for
the stress granule marker G3BP. To demonstrate SYK localization, SYK-deficient DT40 cells
were transiently transfected with NLyn-SYK-eDHFR or Myc-SYK-eDHFR plasmids, plated on
poly-L-lysine-coated coverslips and immunostained for SYK. For BCR retention assays, DT40
cells stably expressing Myc-SYK-eDHFR were plated on poly-L-lysine-coated coverslips and
treated with Texas Red-labeled goat anti-chicken IgM (Rockland) for the indicated times. The cells
were then immunostained for SYK.
After treatment, cells were washed with PBS, fixed with 3.7% formaldehyde in PBS for 10
min, washed twice with PBS, and permeabilized with 0.5% Triton X-100 in PBS for 5 min. They
were then washed three times with PBST (0.1% Tween-20 in PBS) and blocked with 5% goat
serum in PBST for 10 min. The primary antibody was added directly to the blocking buffer, and
incubated overnight at 4°C, then the cells were washed with PBST three times for 5-10 min. Cells
were incubated with secondary antibody in blocking buffer for 1 h at room temperature in the dark,
then washed with PBST three times for 5-10 min. Nuclei were stained with DAPI (Molecular
Probes) for 5 min, cells were briefly washed with PBST to remove excess DAPI, then washed
twice with PBST for 5-10 min, and once each with PBS and ddH2O for 5-10 min. Coverslips were
mounted on glass slides with ProLong Gold Antifade reagent (Invitrogen) for imaging. Slides were
imaged by an EVOS FL fluorescence microscope or Zeiss LSM 710 confocal microscope.

2.6

TMP-Agarose Pull-Down Assay

HEK293T cells stably expressing Myc-SYK-eDHFR or Myc-eDHFR were grown to about
70% confluence on 10 cm culture dishes. Cells were lysed with ice cold NP-40 lysis buffer,
sonicated, and centrifuged at 17,000 × g for 5 min at 4°C. Lysates were pre-cleared by incubating
with Sepharose beads (30 μL) at 4°C for 30 min. Lysates were then incubated with TMP-agarose
beads (5 μL) plus Sepharose beads (30 μL) for 15 min at 4°C. The beads were washed three times
with lysis buffer and transferred to new tubes with the final wash. SDS sample buffer (200 μL)
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was added, and the samples were heated for 5-10 min at 99°C, separated by SDS-PAGE and
immunoblotted for the Myc-epitope.

2.7

Cell Fractionation

MCF7-BD cells stably expressing SYK-EGFP-eDHFR or EGFP-eDHFR were grown to
~70% confluence, then treated with MG132 (100 μM) for 6 h to induce SG formation. Cells were
lysed in ice cold NP-40 lysis buffer, sonicated, and centrifuged at 17,000 × g for 20 min. The pellet
was resuspended in 500 μL SDS sample buffer. The supernatant was mixed 1:1 with 2x SDS
sample buffer. Samples were heated to 99°C for 10 min, and proteins were separated by SDSPAGE. Proteins were detected by Western blotting with antibodies against GFP.

2.8

NFAT- and NFκB-Luciferase Reporter Assays

SYK-deficient DT40 cells were electroporated with 30 μg of the indicated eDHFR-linked
protein expression plasmid or mock plasmid and 10 μg NFAT- or NFκB-luciferase plasmid and
then allowed to recover for 24-48 h. The cells were collected and resuspended in medium lacking
chicken serum at a density of 1×106 cells/mL. Cells were treated with either 1 μM ionomycin plus
50 ng/mL PMA, 0.5% DMSO, 0.5 μg/mL goat anti-chicken IgM (Bethyl Laboratories), anti-IgM
plus 2 μM Latrunculin B (LatB, AdipoGen), or anti-IgM plus the indicated concentration of TMP
dimer for 6 h at 37°C. Luciferase activity was measured using a Promega Luciferase Assay System
kit per manufacturer instructions. All measured values were normalized to the PMA/ionomycin
internal control. All experiments consisted of three technical replicates and were repeated 3-4
times.

2.9

Intracellular Calcium Assay

Intracellular calcium was measured using a Fluo-4 NW Calcium Assay Kit (Invitrogen)
per manufacturer’s protocol. Briefly, DT40 cells stably expressing Myc-SYK-eDHFR were
collected and resuspended in assay buffer at 2 × 107 cells/mL. Cells were aliquoted to a 96-well
plate (50 μL/well) and incubated at 37°C for 1 h. Fluo-4 2x dye was then added (50 μL/well), and
the cells were incubated at 37°C for 30 min and then 25°C for 30 min. Background fluorescence
was measured. Then 25 μL of 5x anti-IgM (10 μg/mL final concentration) or anti-IgM plus TMP
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dimer (10 μM final concentration) was auto-injected. Fluorescence readings were measured every
5 sec over 5 min on a BioTek Synergy4 plate reader. Each treatment condition was repeated in
triplicate and on three different days. Background fluorescence was subtracted, replicates were
averaged, and all values were normalized to peak values.

2.10 ImageJ Analyses
Stress granule size was measured using the ImageJ Analyze Particles function (>Analyze
>Analyze Particles) after subtracting background (>Process >Math >Subtract) and adjusting
automated color threshold (>Image >Adjust >Color Threshold). Cutoff size was set to 5-Infinity.
The stress granules ≥150 pixel2 in each image were counted and divided by the number of DAPIstained nuclei in the same field to calculate stress granules/cell. Colocalization was analyzed using
the ImageJ Coloc2 function (>Analyze >Colocalization >Coloc2). The Pearson correlation
coefficient was used to measure colocaliztion by quantitatively scoring the correlation between the
two fluorophores.
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2.11 Synthesis of TMP Coupled to Agarose Beads

Figure 2.1. Reaction scheme for the preparation of TMP covalently coupled to agarose beads.
The 4’-methoxy group of TMP was cleaved as previously described.5 TMP (10.0 g, 34.5
mmol) was dissolved in 48% hydrobromic acid (120 mL) which had been preheated to 95°C, and
stirred at 95-100°C for 20 min. The heat bath was then removed and sodium hydroxide (50% aq.,
30 mL) was added dropwise. Stirring was then stopped and the reaction mixture was allowed to
cool to room temperature over 2 h, yielding a white precipitate. Precipitated crystals were filtered,
washed with ice-cold water, and allowed to mostly dry in Buchner funnel. They were then
dissolved in boiling water (150 mL) and neutralized to pH 7 by slow addition of aq. ammonium
hydroxide (30% w/w). This solution was then placed at 4°C overnight, resulting in crystal
precipitation. The precipitate was then filtered, rinsed with ice-cold water, and dried in vacuo,
yielding 1 as beige crystals (4.99 g, 53%). 1H NMR (300 MHz, CD3OD) δ ppm: 7.21 (s, 1H), 6.54
(s, 2H), 3.82 (s, 6H), 3.63 (s, 2H).
5-iodovalerate (2) was prepared as previously described,6 with slight modification. Sodium
iodide (6.16 g, 41.1 mmol) was dissolved in dry acetone (26 mL) and brought to reflux. Ethyl 5bromovalerate (5.0 mL, 31.6 mmol) was then added and the reaction was stirred at reflux for 3 h.
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Additional sodium iodide (2.37 g, 15.8 mmol) was then added, and the solution was stirred at
reflux for 1 h. The reaction was cooled, and 13 mL ether was added. The solution was filtered, and
solvent evaporated in vacuo. The residue was dissolved in 40 mL ether, and then washed twice
each with 12-13 mL of 1% NaOH (aq), ddH2O, and brine. The organic fraction was then dried
over sodium sulfate and the solvent removed in vacuo, yielding a pale-yellow oil (3.76 g, 93%).
1

H NMR (300 MHz, CDCl3) δ ppm: 4.01 (q, 2H), 3.08 (t, 2H), 2.22 (t, 2H, 1.75 (m, 2H), 1.64 (m,

2H), 1.15 (t, 3H).
To generate the 4’-substituted phenol 4, 1 (2.00 g, 7.24 mmol), 2 (2.04 g, 7.97 mmol), and
cesium carbonate (4.72 g, 14.48 mmol) were dissolved in DMF (180 mL) and stirred at 70°C for
6 h. Solvent was then removed in vacuo. The crude product was directly purified by flash silica
gel chromatography (DCM → 10% MeOH/DCM), yielding a brown solid (1.55 g, 53%). 3 (1.55
g, 3.82 mmol) was then dissolved in MeOH (7.6 mL) and NaOH (5 M, 2.30 mL, 11.5 mmol) was
added. The reaction was stirred at room temperature for 1 h. The solvent was then removed, water
(26.0 mL) was added, and acidified to pH 4 with 1 M HCl. The precipitate was filtered, rinsed
with ice-cold water, and dried in vacuo, yielding a light brown solid (0.94 g, 66%). 1H NMR (300
MHz, DMSO-d6) δ ppm: 7.48 (s, 1H), 6.53 (s, 2H), 6.34 (s, 2H), 5.95 (s, 2H), 3.76 (t, 2H), 3.70
(s, 6H), 3.52 (s, 2H), 2.24 (t, 2H), 1.61 (m, 4H).
To prepare the immobilized TMP ligand 5, 4 (8.0 mg, 21 μmol) and 1,1’carbonyldiimidazole (4.4 mg, 27 μmol) were dissolved in DMF (1 mL) and mixed at 50°C, 1000
rpm for 30 min in an Eppendorf Thermomixer. CarboxyLinkTM Coupling Gel (1 mL) was washed
with DMF (1 mL x 3), then combined with the activated acid and mixed overnight at 50°C, 1000
rpm. The beads were then centrifuged, and solvent removed. Coupling efficiency was monitored
by UV absorbance of solvent before and after reaction and determined to be 50-60%. The beads
were washed with DMF (1 mL x 3), and N-acetoxysuccinimide (1 mL of 1 M solution in DMF)
was added to the beads and mixed for 2 h at room temperature to protect residual free amines. The
beads were then washed with DMF (1 mL x 3) and PBS (1 mL x 3), and resuspended in 0.05%
NaN3 in PBS (500 μL) to make a 50% slurry. To prepare N-acetoxysuccinimide, Nhydroxysuccinimide (0.50 g, 4.35 mmol) and acetic anhydride (1.24 mL, 13.1 mmol) were
combined and stirred overnight at room temperature. The solvent was removed. Crystals were
filtered and rinsed with hexanes and dried in vacuo, yielding white crystals (0.637 g, 93%). 1H
NMR (CDCl3, 300 MHz) δ ppm: 2.82 (s, 4H), 2.32 (s, 3H).
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2.12 Synthesis of TMP Dimer 6

Figure 2.2. Reaction scheme for the preparation of a TMP dimer.
1 (0.500 g, 1.33 mmol) and 1,1'-carbonyldiimidazole (0.260 g, 1.60 mmol) were dissolved
in DMF (26 mL) and stirred at room temperature for 30 min. Diethylenetriamine (72 μL, 0.66
mmol) was then added, and the reaction was stirred at room temperature for ~24 h. The solvent
was then removed in vacuo. The crude product was purified by HPLC (5% → 25% ACN/H2O
over 1 h), and fractions appearing to contain product were screened by MALDI MS. Fractions
containing pure product were pooled and lyophilized. 1H NMR (300 MHz, DMSO-d6) δ ppm:
7.22 (s, 2H), 6.56 (s, 4H), 3.91 (s, 4H), 3.80 (s, 12H), 3.66 (s, 4H), 3.49 (m, 4H), 3.18 (m, 4H),
2.36 (m, 4H), 1.85 (m, 4H), 1.72 (m, 4H). MALDI MS (m + H): 820.4413 (calculated: 819.95)

2.13 Synthesis of TMP-Peptides
The TMP-tagged peptides were synthesized using solid-phase peptide chemistry with a
Prelude Parallel Peptide synthesizer (Protein Technologies). Coupling of standard Fmoc-protected
amino acids (Peptides International) was achieved using HCTU with N-methylmorpholine in DMF
for two 10 min couplings. Fmoc deprotection was performed using 20% piperidine in DMF for
two 2.5 min cycles. 1 was manually added (2 mL of 100 mM TMP solution in DMF) to the peptide
reaction, and coupling was performed using HCTU and NMM in DMF for 8 h. Side chain
deprotection and peptide cleavage from the resin was performed using 5 mL of
TFA/water/EDT/TIS (94:2.5:2.5:1). The peptides were precipitated and washed three times with
cold diethyl ether, dissolved in acetonitrile/water/TFA (50:50:0.1), flash frozen, and lyophilized.
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The peptides were purified using a C18 reverse-phase column on an Agilent 1200 preparative
HPLC system. The peptides were characterized using liquid chromatography mass spectrometry
(LC-MS)

on

an

Accela/LTQ

system

(Thermo-Finnegan)

and

matrix-assisted

laser

desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/TOF) on a Voyager 4800
instrument (Applied Biosystems).
TMP-peptide conjugates synthesized included Nuclear Localization Sequence (TMPSPKKKRK), Nuclear Export Sequence (TMP-SALQKKLEELELDE), and CaaX Box sequence
(TMP-GPGCMSCKCVLS).

2.14 Synthesis of TMP-Aryl Azides
Boc-protected 3-bromopropylamine 7 (Figure 2.3) was prepared as previously described.7
3-Bromopropylamine hydrobromide (3.0 g, 13.7 mmol), triethylamine (2.1 mL, 15.1 mmol), and
di-tert-butyl dicarbonate (3.5 mL, 15.2 mmol) were dissolved in DCM (mL) and stirred overnight
at room temperature. Solvent was removed in vacuo, and the product was purified by silica gel
chromatography (20% EtOAc/hexanes), yielding a clear, light yellow oil (3.1 g, 93.4%) that
crystalized upon standing. 1H NMR (300 MHz, CDCl3) δ ppm: 4.88 (s, 1H), 3.37 (m, 2H), 3.19 (t,
2H), 1.98 (m, 2H), 1.37 (s, 9H).
To prepare the 4’-(3-aminopropyl) TMP derivative 8, 1 (0.20 g, 0.73 mmol) and potassium
tert-butoxide (0.16 g, 1.46 mmol) were dissolved in DMSO (7.0 mL) and stirred at room
temperature. 7 was then added, and the reaction was stirred for 2 h at room temperature. Water (10
mL) was added, and the reaction was extracted with DCM (10 mL x 3). The organic fraction was
then washed with water (20 mL x 2) and brine (20 mL), dried over Na2SO4, and concentrated. The
product was purified by silica gel chromatography (2% → 10% MeOH/DCM), yielding a light
yellow solid (0.19 g, 61.8%). The product (0.10 g, 0.24 mmol) was then dissolved in 1:1
TFA:DCM (0.5 mL) and stirred for 1 h at room temperature. The reaction was cooled to 0 °C, and
the pH was adjusted to ~8 by slow addition of saturated NaOH in MeOH. The solvent was then
removed in vacuo. This product was used in the next step without further characterization.
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Figure 2.3. Reaction scheme for preparation of TMP-aryl azide 10
To prepare the aryl azide derivative 9, 4-azidobenzoic acid (0.10 g, 0.61 mmol) and 1,1’carbonyldiimidazole were stirred in DCM for 15 min at room temperature. Methyl 6aminohexanoate hydrochloride (0.11 g, 0.62 mmol) and triethylamine (0.103 mL, 0.74 mmol)
were then added and the reaction was stirred overnight at room temperature. The solvent was
removed in vacuo, and the product was purified by silica gel chromatography (40%
EtOAc/hexanes), yielding a light yellow solid (0.16 g, 88.6%). The product (0.16 g, 0.55 mmol)
was then dissolved in MeOH (1.0 mL), NaOH (0.328 mL, 5 M aq) was added, and the reaction
was stirred for 1 h at room temperature. The solvent was removed, and the product was
resuspended in ddH2O (3.6 mL). The pH was adjusted to ~4 by slow addition of 1 M HCl. The
white precipitate was filtered, rinsed with cold ddH2O, and dried in vacuo, yielding a white solid
(0.11 g, 75.2%). 1H NMR (500 MHz, DMSO-d6) δ ppm: 8.44 (t, 1H), 7.86 (d, 2H), 7.19 (d, 2H),
3.22 (q, 2H), 2.19 (t, 2H), 1.51 (m, 4H), 1.29 (m, 2H).
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To prepare the TMP-aryl azide derivative 10, 8 (0.24 mmol) and 1,1’-carbonyldiimidazole
(0.047 g, 0.29 mmol) were dissolved in DMF (1.2 mL) and stirred for 30 min at room temperature.
9 (0.068 g, 0.24 mmol) in DMF (3.6 mL) was then added, and the reaction was stirred overnight
at room temperature. The reaction was purified by silica gel chromatography (2% → 6%
MeOH/DCM), yielding a light yellow solid (76.9 mg, 54.2%). 1H NMR (500 MHz, DMSO-d6) δ
ppm: 8.43 (t, 1H), 7.86 (d, 2H), 7.72 (t, 1H), 7.46 (s, 1H), 7.18 (d, 2H), 6.88 (s, 2H), 6.56 (s, 2H),
6.48 (s, 2H), 3.79 (t, 2H), 3.71 (s, 6H), 3.54 (s, 2H), 3.22 (m, 2H), 3.16 (m, 2H), 2.04 (t, 2H), 1.70
(m, 2H), 1.49 (m, 4H), 1.25 (m, 2H).

Figure 2.4. Reaction scheme for coupling TMP to a nitro-substituted aryl azide.
1-Fluoro-2-nitro-4-azidobenzene 11 was prepared as previously described.8 4-fluoro-3nitroaniline (0.95 g, 6 mmol) was dissolved in warm (50-55 °C) concentrated HCl (6 mL), and
then cooled to -5 °C. A solution of sodium nitrite (0.50 g, 7.3 mmol) in 4 mL of water was then
added dropwise. The solution was stirred for 30 min at -5 °C, and a cold solution (0ºC) of sodium
azide (0.51 g, 7.5 mmol) in 10 mL of water was added dropwise. Light orange crystals precipitated
and were filtered and rinsed with cold water, yielding orange crystals (0.81 g, 73.8%). 1H NMR
(500 MHz, CDCl3) δ ppm: 7.72 (d, 1H), 7.29 (m, 2H).
To generate 4-(6-aminohexylamine)-3-nitrophenylazide 12, 1,6-hexanediamine was
melted at 45-50 °C, 11 (0.20 g, 1.1 mmol) was added, and the reaction was stirred at 45-50 °C for
1.5 h. The reaction was cooled to room temperature, ethyl acetate (20 mL) was added and washed
with water (25 mL x2), saturated aqueous NaHCO3 (25 mL), and brine (25 mL). The organic
fraction was dried over Na2SO4 and concentrated, yielding a red solid (0.211 g, 68.9%). 1H NMR
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(500 MHz, CDCl3) δ ppm: 8.00 (s, 1H), 7.82 (s, 1H), 7.10 (d, 1H), 6.86 (d, 1H), 3.28 (t, 2H), 2.69
(t, 2H), 2.16 (m, 4H), 1.46 (m, 4H), 1.39 (t, 2H).
To couple TMP to 12, 4 (0.10 g, 0.27 mmol) and 1,1’-carbonyldiimidazol (0.054 g, 0.33
mmol) were dissolved in DMF (5.4 mL) and stirred at 50 °C for 30 min. 4-(6-aminohexylamine)3-nitrophenyl azide 12 was then added, and the reaction was stirred overnight at 50 °C. DMF was
removed in vacuo, and the reaction was purified by silica gel chromatography (2% → 10%
MeOH/DCM), yielding a red solid (72.5 mg, 42.2%). 1H NMR (500 MHz, CDCl3) δ ppm: 8.00 (s,
1H), 7.86 (s, 1H), 7.72 (s, 1H), 7.11 (d, 1H), 6.87 (d, 1H), 6.37 (s, 2H), 5.70 (s, 1H), 4.96 (s, 2H),
4.68 (s, 2H), 3.96 (t, 2H), 3.78 (s, 6H), 3.64 (s, 2H), 3.26 (m, 4H), 2.29 (t, 2H), 1.82 (m, 2H), 1.77
(m, 2H), 1.71 (m, 2H), 1.52 (m, 2H), 1.45 (m, 2H), 1.38 (m, 2H).
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2.15 Synthesis of TMP-azide for Click Reaction

Figure 2.5. Reaction scheme for alkylation of 1 with a flexible linker terminating in an azide.
The 4’-(6-bromohexanoxy)-TMP derivative 14 was prepared as described previously.9 1
(2.5 g, 9.1 mmol) and potassium tert-butoxide (1.2 g, 10.7 mmol) were dissolved in dry DMSO
(55 mL). 1,6-Dibromohexane (7.0 mL, 45.51 mmol) was then added, and the reaction was stirred
for 1.5 h at room temperature. Water (50 mL) was added, and the aqueous layer was extracted with
EtOAc (50 mL x 2). The combined organic fractions were then washed with water (20 mL), dried
over Na2SO4, and solvent was removed in vacuo. The product was purified by silica gel
chromatography (5% MeOH/DCM), yielding a brown solid (0.44 g, 11.1%). 1H NMR (300 MHz,
CDCl3) δ ppm: 7.77 (s, 1H), 6.37 (s, 2H), 4.79 (s, 2H), 3.95 (t, 2H), 3.78 (s, 6H), 3.65 (s, 2H), 3.41
(t, 2H), 1.91 (t, 2H), 1.78 (t, 2H), 1.49 (t, 4H).
The 4’-(6-azidohexanoxy)-TMP derivative 15 was prepared as described previously.10 14
(0.41 g, 0.94 mmol) and NaN3 (0.091 g, 1.4 mmol) were stirred in DMF (1.4 mL) for at room
temperature for 4 h. Water (5 mL) was added to the reaction mixture, and extracted with EtOAc
(10 mL x 3). The combined organic fractions were washed with brine (10 mL) and 10% aqueous
LiCl (10 mL), dried over Na2SO4, and solvent was removed in vacuo. 1H NMR (300 MHz, CDCl3)
δ ppm: 7.69 (s, 1H), 6.30 (s, 2H), 4.88 (s, 2H), 4.65 (s, 2H), 3.88 (t, 2H), 3.71 (s, 6H), 3.57 (s, 2H),
3.20 (t, 2H), 1.68 (t, 2H), 1.56 (t, 2H), 1.39 (t, 4H).
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2.16 Synthesis of Glycated TMP

Figure 2.6. Reaction scheme for the preparation of a carbohydrate-substituted TMP analog.
The acetyl-protected glycated TMP analog 16 was prepared as previously described, with
slight modification.11 1 (1.0 g, 3.6 mmol) and K2CO3 (0.81 g, 5.4 mmol) were stirred in dry DMSO
(40 mL) at room temperature for 10 min. 2,3,4,6-Tetra-O-acetyl-α-D-glucopyranosyl bromide was
then added and the reaction was stirred overnight at 65-70°C. The reaction was then cooled to
room temperature, water (40 mL) was added, and extracted with DCM (80 mL × 3). The organic
phase was washed with water (200 mL × 2) and brine (200 mL), dried over Na2SO4, and
concentrated. The product was purified by silica gel chromatography (2% → 20% MeOH/DCM),
yielding a light brown solid (0.21 g, 9.8%). 1H NMR (500 MHz, CDCl3) δ ppm: 7.58 (s, 1H), 6.31
(s, 2H), 5.40 (s, 2H), 5.25-5.16 (m, 3H), 5.14 (s, 2H), 4.95 (d, 1H), 4.19 (d, 1H), 4.04 (d, 1H), 3.67
(s, 6H) 3.62 (d, 1H), 3.54 (s, 2H), 1.95 (s, 12H).
The glucose moiety was then deprotected as previously described,12 with slight
modification, yielding glycated TMP 17. 16 (0.21 g, 0.35 mmol) was dissolved in dry MeOH (3.5
mL). Sodium methoxide (0.19 g, 3.54 mmol) was then added, and the reaction was stirred at room
temperature for 1 h. The pH was then neutralized with Amberlyst 15 ion exchange resin. The
reaction mixture was filtered, rinsed with MeOH, concentrated, and lyophilized, yielding a light
brown powder (0.11 g, 68.9%). 1H NMR (500 MHz, DMSO-d6) δ ppm: 8.45 (s, 4H), 7.53 (s, 1H),
6.55 (s, 2H), 6.10 (s, 2H), 5.70 (s, 2H), 4.83 (d, 1H), 3.70 (s, 6H), 3.57 (d, 1H), 3.55 (d, 1H), 3.51
(s, 2H), 3.42 (d, 1H), 3.38 (d, 1H), 3.17 (m, 2H).
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MODULATION OF BCR SIGNALING BY THE
INDUCED DIMERIZATION OF RECEPTOR-ASSOCIATED SYK

3.1

Introduction

The B cell antigen receptor (BCR) is a macromolecular complex consisting of a membranebound immunoglobulin and the heterodimeric co-receptors CD79A and CD79B.1 The cytoplasmic
tails of CD79A and CD79B each contain two conserved tyrosines that constitute part of an
immunoreceptor tyrosine-based activation motif (ITAM).2 Binding of antigen to the BCR results
in rapid ITAM phosphorylation, which then serves as a scaffold for docking of signaling
components.2-4 Although the mechanism by which binding of antigen initiates phosphorylation of
ITAM tyrosines is not well understood, several models seek to explain the phenomenon. The most
widely accepted model is the BCR clustering model, where binding of polyvalent antigens induces
clustering of BCR complexes,5, 6 thus bringing signaling components into close enough proximity
to activate their functions. This was first proposed due to experiments that demonstrated that
divalent anti-BCR antibodies were able to activate BCR signaling, while monovalent Fab
fragments were not.7-11 A second suggested model is that antigen binding induces a conformational
change in the BCR that ultimately initiates signaling.12 More recent research points to a third model
called the dissociation-activation model. This proposes that the BCR exists as auto-inhibited
oligomers, or microclusters, that are opened and activated upon the binding of antigen.13, 14 Thus,
actin depolymerization alone, which mimics the transient actin depolymerization that is induced
by BCR engagement, induces signaling by opening the BCR oligomer even without BCR
crosslinking.15-18
Despite the differences in these models, they all agree that the extent of B cell activation
relies on the receptor affinity for the antigen, as well as antigen dose and valency.6 Recent studies
using synthetic antigens have demonstrated that while low valency antigens are capable of
activating BCR signaling, high valency antigens promote a greater degree of signaling, and
successfully induce production of antibodies in vivo.6, 19, 20 Thus, more BCR crosslinking induces
a greater response.
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Both signaling and aggregation of antigen-bound receptors are enhanced by intracellular
components. Specifically, the non-receptor tyrosine kinase SYK promotes a positive feedback loop
to enhance ITAM phosphorylation and signaling.21,

22

SYK consists of two N-terminal SH2

domains and a C-terminal kinase domain.1 Binding of the tandem SH2 domains to doubly
phosphorylated ITAMs confers a conformational change that activates SYK and allows it to
phosphorylate downstream signaling proteins.23 Studies have shown that, upon binding to the
doubly phosphorylated ITAM, SYK is able to phosphorylate neighboring ITAMs to recruit more
SYK and enhance signaling in a positive feedback loop.22 Additionally, SYK binding to the
phosphorylated ITAM further activates the receptor through an inside-out signaling mechanism to
amplify signaling.21
At the termination of signaling, the BCR complex is internalized via a clathrin- and actindependent mechanism, and the antigen is processed for presentation by MHC class II complexes.24,
25

The receptor proximal tyrosine kinase LYN and SYK differentially modulate receptor

internalization. While LYN is required for internalization,26 SYK prolongs BCR residence at the
plasma membrane. The BCR of SYK-deficient cells is rapidly internalized upon antigen
engagement, while the BCR of SYK-sufficient cells remains clustered at the plasma membrane for
a longer period of time.26 SYK inhibition results in rapid BCR internalization.27
I hypothesized, therefore, that enhancing the interaction between SYK molecules
associated with clustered BCR complexes would augment receptor retention at the membrane. To
investigate this, I developed and employed a novel chemical inducer of dimerization to selectively
aggregate SYK when bound to the BCR. I used a known interaction of SYK with stress granules
(SGs)28 to monitor the effects of the dimerizer on aggregation of SYK-associated complexes. I
demonstrate that SYK dimerization does modulate BCR signaling and increase the retention of
kinase-BCR complexes at the plasma membrane. Interestingly, this induced dimerization plays a
selective role in enhancing signaling from the receptor to the activation of NFAT.

3.2
3.2.1

Results

eDHFR-tagged SYK Binds TMP
I sought to develop a process for inducing the dimerization of SYK in intact cells by first

generating a fusion protein containing a subunit with small molecule binding capabilities. For this,
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I created expression constructs coding for proteins fused with E. coli dihydrofolate reductase
(eDHFR). eDHFR binds the small molecule trimethoprim (TMP), a competitive inhibitor, with
very high affinity (Kd = 9.1 nM). TMP can be selectively modified without significantly affecting
its binding.29, 30 These binding characteristics, together with the small size of eDHFR (18 kDa),
make this an ideal system for using chemical genetics to study biological processes. I generated
constructs for the expression of EGFP- and Myc-epitope tagged forms of SYK (SYK-EGFPeDHFR and Myc-SYK-eDHFR, respectively) and, as controls, EGFP-eDHFR and Myc-eDHFR.
Transfections in HEK293T cells indicated that these forms could be stably expressed (Figure 3.1).

Figure 3.1. eDHFR-linked fusion proteins are stable. HEK293T cells were transfected with either
recombinant SYK or control eDHFR plasmids and stable transfectant cell lines were produced.
Western blot analysis of lysates from control HEK293T cells (Crtl) or stable transfectant
HEK293T cells using antibodies against SYK, GFP or the Myc-epitope tag (Myc).
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To determine if eDHFR-tagged proteins retained the ability to bind TMP, I synthesized a
form of TMP covalently bound to agarose beads using the scheme outlined in Figure 2.1. The TMP
4’-methoxy moiety was first deprotected, then alkylated with a five-carbon linker terminating in a
carboxylic acid. This was then covalently linked to agarose beads harboring primary amines via
amide coupling. Residual free amines were protected by incubation with N-acetoxysuccinimide.
These beads (Figure 3.2) were used in pull-down experiments to isolate tagged proteins from
lysates of HEK293T cells stably expressing either Myc-SYK-eDHFR or Myc-eDHFR. As shown
in Figure 3.3, both proteins were effectively pulled down by these beads, demonstrating the ability
of the tagged proteins to bind TMP.

Figure 3.2. Chemical structure of TMP covalently bound to agarose beads.
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Figure 3.3. eDHFR-tagged proteins bind TMP. Lysates from HEK293T cells expressing MycSYK-eDHFR or Myc-eDHFR were adsorbed to immobilized TMP. Proteins in lysates (Input) or
bound to beads were detected by Western blotting using anti-Myc epitope (Myc) antibodies.
3.2.2

TMP Dimer Induces SYK Aggregation
To generate a small molecule dimerizer of eDHFR-tagged proteins, I coupled two

molecules of TMP together, separated by a 17-atom spacer (Figure 3.4). To accomplish this, I first
alkylated TMP as previously mentioned. I then employed amide coupling with diethylenetriamine
and an excess of TMP to generate a dimer with a long, flexible linker. To validate that this TMP
dimer was capable of inducing SYK aggregation, I took advantage of a known interaction to
visualize SYK when present in a large complex in live cells.
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Figure 3.4. Chemical structure of TMP dimer.
3.2.2.1 SYK Localizes to Stress Granules (SGs)
SGs are large aggregates of protein and mRNA, or ribonucleoprotein (RNP) granules, that
form in response to stresses that stall mRNA translation initiation. These include heat shock,
glucose depravation, oxidative stress, proteasome inhibition, viral infection, or exposure to
arsenite.31, 32 An initial observation from a protein-protein interaction screen carried out in our
laboratory identified G3BP, a known component of SGs, as a SYK-binding protein.33 Our lab
followed up this observation to demonstrate a physical interaction of SYK with SGs.28 In this study,
we showed that the treatment of SYK-EGFP-expressing MCF7 cells with either the proteasome
inhibitor MG132 or sodium arsenite (SA) led to the extensive formation of SGs, the co-localization
of SYK-EGFP to these SGs, and the appearance of phosphotyrosine-containing proteins within
these complexes.28
3.2.2.2 SYK Dimerization Induced by TMP Dimer Modulates SG Size
SGs lack membranes and form instead by liquid-liquid phase separation.34 These droplets
are able to undergo fission and fusion within the cell. I used this system to probe the ability of the
TMP dimer to aggregate SYK-associated complexes. I induced SG formation in MCF7-BD cells
stably expressing Myc-SYK-eDHFR or Myc-eDHFR in the absence or presence of added TMP
dimer to determine if dimerization could promote the formation of larger droplets. With addition
of the TMP dimer, the number of large SGs (≥150 pixel2) per cell showed a five-fold increase in
cells expressing Myc-SYK-eDHFR, but remained unchanged in cells expressing Myc-eDHFR
(Figure 3.5).
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Figure 3.5. The size of cellular ribonuclear protein aggregates increased when SYK and TMP
dimerizing agent were present. A. MCF7-BD cells stably expressing Myc-eDHFR, Myc-SYKeDHFR or SYK-EGFP-eDHFR were treated with or without MG132 to induce the formation of
SGs in the presence or absence of TMP dimer. Cells were fixed and stained with antibodies against
G3BP (red) and stained with DAPI to visualize nuclei (blue). Bar, 50 μm. B. TMP dimer increases
the number of large SGs in cells expressing eDHFR-tagged SYK. Large SGs were counted in cells
treated as described in panel A. The histogram represents average +/- SEM of 80-100 cells from
experiments repeated three times. * P < 0.05.
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3.2.2.3 SYK Activity is not Required for TMP Dimer-induced Increase in SG Size
Previous experiments had determined that the localization of SYK to SGs did not require
its catalytic activity as an inactivated construct of SYK also localized to SGs. 28 I took advantage
of the observation that the addition of eDHFR to SYK-EGFP led to the formation of an inactive
kinase. This is illustrated below in an experiment in which MCF7-BD cells stably expressing SYKEGFP, SYK-EGFP-eDHFR or EGFP-eDHFR were treated with SA for 2 h. Lysates were
immunoblotted with antibodies against phosphotyrosine (Figure 3.6). While SA induced extensive
tyrosine phosphorylation in cells expressing SYK-EGFP, phosphotyrosine-containing proteins
were nearly undetectable in cells expressing SYK-EGFP-eDHFR or EGFP-eDHFR. I used the
inactive SYK-EGFP-eDHFR construct to determine if the change in SG size in response to the
TMP dimer was exclusively due to SYK aggregation as opposed to SYK activity.

Figure 3.6. SYK-EGFP-eDHFR is inactive. MCF7-BD cells stably expressing SYK-EGFP, SYKEGFP-eDHFR, or EGFP-eDHFR were treated with SA for 2 h. Tyrosine phosphorylation was
detected by Western blotting using anti-phosphotyrosine antibodies.
First, to demonstrate that SG-inducing conditions promote SYK-EGFP-eDHFR
translocation, I performed cell fractionation experiments because SGs are poorly detergent-soluble.
After treating MCF7-BD cells stably expressing SYK-EGFP-eDHFR or EGFP-eDHFR with
MG132 for 6 h to induce SG formation, cells were lysed and separated into detergent-soluble and
-insoluble fractions by centrifugation. SYK-EGFP-eDHFR moved to the detergent-insoluble
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fraction in an MG132-dependent manner. Although a small amount of EGFP-eDHFR was found
in the detergent-insoluble fraction, this was not MG132-dependent (Figure 3.7). I then repeated
the SG aggregation experiment with MCF7-BD cells stably expressing SYK-EGFP-eDHFR.
These cells exhibited an eight-fold increase in the number of SG ≥150 pixel2 (Figure 3.5).

Figure 3.7. Stresses that induce SG formation result in redistribution of SYK to detergentinsoluble fraction. MCF7-BD cells stably expressing SYK-EGFP-eDHFR or EGFP-eDHFR were
treated with MG132 (100 mM) for 6 h to induce SG formation. NP40 cell lysates were centrifuged
at 17,000 × g for 20 min. The pellet (insoluble fraction) was resuspended in 500 L SDS sample
buffer. The supernatant (soluble fraction) was mixed 1:1 with SDS sample buffer. Proteins were
separated by SDS-PAGE and detected by Western blotting with antibodies against GFP.
3.2.2.3.1 MS analysis of MCF7-BD cells treated with SA
The ability of the TMP dimer to induce SG aggregation was consistent with an extensive
interaction of SYK with these RNP complexes. I took advantage of this observation to further
explore the interaction of SYK with SGs. The interaction of SYK with a protein complex in cells
can leave behind “fingerprints” in the form of phosphotyrosines on multiple components of that
complex giving clues to its localization. In our previous phosphoproteomic analyses, we had
treated SYK-expressing cells with sodium pervanadate (PV), which is a general tyrosine
phosphatase inhibitor and an activator of SYK, to identify SYK-dependent substrates.33, 35 The
treatment of SYK-expressing cells with PV leads to a dramatic increase in phosphotyrosine content,
but does not induce SG formation. To examine where these substrates are localized, MCF7-BD
cells ectopically expressing various amounts of SYK-EGFP were treated with PV, fixed and
stained with antibodies against phosphotyrosine (Figure 3.8). The level of phosphotyrosine was
higher in cells expressing higher levels of SYK-EGFP as expected. These phosphotyrosine-
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containing proteins were distributed throughout the cell and were especially prominent at the cell
periphery. The treatment of MCF7 cells expressing SYK-EGFP with SA, which does result in
robust SG formation, also greatly enhanced SYK-dependent tyrosine phosphorylation.28 With this
treatment, however, increased phosphotyrosine levels were found predominantly in cytoplasmic
puncta (Figure 3.8). These are characteristic of SGs and are consistent with our previous findings
of increased phosphotyrosine in SGs formed in MCF7 cells treated with MG132.28
Because SG-inducing stresses promote SYK translocation to and tyrosine phosphorylation
within cytoplasmic puncta, I hypothesized that treatment with an inducer of SG formation would
result in a unique phosphorylation profile compared to treatment with PV. I performed a
phosphoproteomic study to detect and compare SYK substrates under conditions in which SG
formation was either induced or not induced using SA or PV. I compared MCF7-BD cells stably
expressing SYK-EGFP when treated with SA to cells treated with PV. As a control, I also
compared SYK-EGFP-expressing cells treated with SA to MCF7-BD cells, which lack SYK, to
further identify those phosphorylation events that were SYK-dependent.
MCF7-BD cells with or without stable SYK-EGFP expression were treated with PV for 30
min or SA for 2 h at 37°C. Cells were then washed, pelleted, and lysed. Lysates were cleared by
centrifugation at 1000 × g to remove cell debris, but not detergent-insoluble granules. Proteins
from each sample were digested with trypsin and immunoprecipitated with antibodies against
phosphotyrosine. Isolated phosphopeptides were enriched using polymer-based metal ion affinity
capture (PolyMAC) as previously described.36 The enriched phosphopeptides were then analyzed
by LC-MS/MS. This experiment was done in collaboration with Justine Arrington in the laboratory
of Andy Tao.
Proteins from cells treated with SA whose phosphorylation on tyrosine was dependent on
both SYK and SA are listed in Table 3.1, while those phosphorylated following treatment with PV
are listed in Table 3.2.
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Figure 3.8. PV induces general tyrosine phosphorylation, while SA induces localized tyrosine
phosphorylation. A. MCF7-BD cells expressing SYK-EGFP (green) were treated with PV for 30
min and stained with antibodies against phosphotyrosine (pTyr, red). B. MCF7-BD cells
expressing SYK-EGFP were treated without (Ctrl) or with SA for 2 h, and stained with antibodies
against phosphotyrosine (pTyr, red). Bar, 20 μm.
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Table 3.1. List of proteins phosphorylated in a SA- and SYK-dependent manner. MCF7-BD cells
with or without SYK-EGFP expression were treated with SA for 2 h. Tyrosine-phosphorylated
peptides were generated, isolated and identified by MS/MS.

Accession

Gene Name

P19387

POLR2C

Q9BYM8

RBCK1

A0A0B4J1T2

AR

Q9UPY3

DICER1

P52943

CRIP2

Q9H3U1

UNC45A

Q9NQ86
P03372
Q9NZL4

TRIM36
ESR1
HSPBP1

Q6KB66

KRT80

O43143

DHX15

Q8WVV4

POF1B

A0A0A0MQR1 MAP4K5
O43264

ZW10

Q68DH5

LMBRD2

Q70EL1

USP54

Q2NKX8

ERCC6L

Q8IWR0

ZC3H7A

Q92973
Q9C0H5
Q5JVF3
Q12959
Q7Z569

TNPO1
ARHGAP39
PCID2
DLG1
BRAP

Q9NP77

SSU72

Phospho(Y)
Positions
DNA-directed RNA polymerase II Phospho [Y142;
subunit RPB3
Y220]
RanBP-type and C3HC4-type zinc Phospho [Y224;
finger-containing protein 1
Y262]
Phospho [Y364;
Androgen receptor
Y365]
Phospho
Endoribonuclease Dicer
[Y1438]
Cysteine-rich protein 2
Phospho [Y77]
Phospho [Y602;
Protein unc-45 homolog A
Y934]
E3 ubiquitin-protein ligase TRIM36
Phospho [Y396]
Estrogen receptor
Phospho [Y219]
Hsp70-binding protein 1
Phospho [Y337]
Phospho [Y273;
Keratin, type II cytoskeletal 80
Y288]
Pre-mRNA-splicing
factor
ATPPhospho [Y13]
dependent RNA helicase DHX15
Protein POF1B
Phospho [Y139]
Mitogen-activated protein kinase kinase
Phospho [Y20]
kinase kinase
Centromere/kinetochore protein zw10
Phospho [Y619]
homolog
LMBR1 domain-containing protein 2
Phospho [Y290]
Inactive ubiquitin carboxyl-terminal Phospho [Y1233;
hydrolase 54
Y1407]
DNA excision repair protein ERCC-6- Phospho
like
[Y1126]
Zinc finger CCCH domain-containing Phospho [Y499;
protein 7A
Y893]
Transportin-1
Phospho [Y150]
Rho GTPase-activating protein 39
Phospho [Y448]
PCI domain-containing protein 2
Phospho [Y204]
Disks large homolog 1
Phospho [Y760]
BRCA1-associated protein
Phospho [Y389]
RNA polymerase II subunit A C-terminal
Phospho [Y116]
domain phosphatase SSU72
Description
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Table 3.1 continued
Q9BY32
Q96JH7

ITPA
VCPIP1

Q08357

SLC20A2

Q9BRK4

LZTS2

Q9UI30

TRMT112

O95396

MOCS3

Q96RS0
Q00653
Q96JK2
Q9NWZ8
Q9BWF3
A0A0A0MSG2

TGS1
NFKB2
DCAF5
GEMIN8
RBM4
FHL2

Q9ULD2

MTUS1

Q9UJY4

GGA2

P57678

GEMIN4

Q96II8

LRCH3

G3V4K3

VIPAS39

Q96PE3

INPP4A

Q9C0B7

TANGO6

P36954

POLR2I

P25054

APC

Q9Y3Z3

SAMHD1

E7EQN9

INPP4B

Q05048
Q9BTE1

CSTF1
DCTN5

Q9UIV1

CNOT7

Inosine triphosphate pyrophosphatase
Deubiquitinating protein VCIP135
Sodium-dependent phosphate transporter
2
Leucine zipper putative tumor suppressor
2
Multifunctional
methyltransferase
subunit TRM112-like protein
Adenylyltransferase
and
sulfurtransferase MOCS3
Trimethylguanosine synthase
Nuclear factor NF-kappa-B p100 subunit
DDB1- and CUL4-associated factor 5
Gem-associated protein 8
RNA-binding protein 4
Four and a half LIM domains protein 2
Microtubule-associated tumor suppressor
1
ADP-ribosylation factor-binding protein
GGA2
Gem-associated protein 4
Leucine-rich repeat and calponin
homology domain-containing protein 3
Spermatogenesis-defective protein 39
homolog
Type I inositol 3,4-bisphosphate 4phosphatase
Transport and Golgi organization protein
6 homolog
DNA-directed RNA polymerase II
subunit RPB9
Adenomatous polyposis coli protein
Deoxynucleoside
triphosphate
triphosphohydrolase SAMHD1
Type II inositol 3,4-bisphosphate 4phosphatase
Cleavage stimulation factor subunit 1
Dynactin subunit 5
CCR4-NOT
transcription
complex
subunit 7

Phospho [Y45]
Phospho [Y663]
Phospho [Y354]
Phospho [Y358]
Phospho [Y74]
Phospho [Y312]
Phospho [Y67]
Phospho [Y39]
Phospho [Y617]
Phospho [Y171]
Phospho [Y190]
Phospho [Y213]
Phospho [Y275]
Phospho [Y269]
Phospho [Y284]
Phospho [Y490]
Phospho [Y37)]
Phospho [Y355]
Phospho [Y565]
Phospho [Y44]
Phospho
[Y1135]
Phospho [Y396]
Phospho [Y516]
Phospho [Y67]
Phospho [Y13]
Phospho [Y277]
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Table 3.1 continued

O95786

DDX58

Q8IX90

SKA3

Q04206

RELA

Q8TD26

CHD6

O14545

TRAFD1

Q5SZD1
P26640
Q15181

C6orf141
VARS
PPA1

Probable ATP-dependent RNA helicase
DDX58
Spindle and kinetochore-associated
protein 3
Transcription factor p65
Chromodomain-helicase-DNA-binding
protein 6
TRAF-type
zinc
finger
domaincontaining protein 1
Uncharacterized protein C6orf141
Valine--tRNA ligase
Inorganic pyrophosphatase

Q13315

ATM

Serine-protein kinase ATM

Q9H992

MARCH7

Q8IWZ3

ANKHD1

Q8IU60
P54577

DCP2
YARS

P40337

VHL

Q9NRX4

PHPT1

Q12980

NPRL3

Q99700

ATXN2

Q9HC35

EML4

A0MZ66
Q9UGI8
Q86V48
Q96IZ0
P50552

SHTN1
TES
LUZP1
PAWR
VASP

P26196

DDX6

O43303
Q9NSV4
Q9Y6K5
Q9UBS8
Q8TF72
Q9Y2Z0

CCP110
DIAPH3
OAS3
RNF14
SHROOM3
SUGT1

E3 ubiquitin-protein ligase MARCH7
Ankyrin repeat and KH domaincontaining protein 1
m7GpppN-mRNA hydrolase
Tyrosine--tRNA ligase, cytoplasmic
Von Hippel-Lindau disease tumor
suppressor
14 kDa phosphohistidine phosphatase
Nitrogen permease regulator 3-like
protein
Ataxin-2
Echinoderm microtubule-associated
protein-like 4
Shootin-1
Testin
Leucine zipper protein 1
PRKC apoptosis WT1 regulator protein
Vasodilator-stimulated phosphoprotein
Probable ATP-dependent RNA helicase
DDX6
Centriolar coiled-coil protein of 110 kDa
Protein diaphanous homolog 3
2'-5'-oligoadenylate synthase 3
E3 ubiquitin-protein ligase RNF14
Protein Shroom3
Protein SGT1 homolog

Phospho [Y40]
Phospho [Y39]
Phospho [Y152]
Phospho [Y374]
Phospho [Y108]
Phospho [Y130]
Phospho [Y601]
Phospho [Y169]
Phospho
[Y2969]
Phospho [Y315]
Phospho [Y472]
Phospho [Y370]
Phospho [Y388]
Phospho [Y185]
Phospho [Y116]
Phospho [Y46]
Phospho [Y471]
Phospho [Y226]
Phospho [Y24]
Phospho [Y251]
Phospho [Y952]
Phospho [Y177]
Phospho [Y39]
Phospho [Y473]
Phospho [Y602]
Phospho [Y673]
Phospho [Y4]
Phospho [Y364]
Phospho [Y501]
Phospho [Y47]
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Table 3.1 continued

Q460N5
Q5VT97
Q9NVM4
Q13191
P49757
Q9NW64
Q08345
Q96P70
Q6PIW4
Q6QNK2
P58546
Q8N4S9
O75665
P21359
Q9UKA4
Q9NZU5
Q6PJT7
Q8IWR0

Phospho
[Y1472]
Phospho
SYDE2
Rho GTPase-activating protein SYDE2
[Y1112]
PRMT7
Protein arginine N-methyltransferase 7
Phospho [Y24]
CBLB
E3 ubiquitin-protein ligase CBL-B
Phospho [Y337]
NUMB
Protein numb homolog
Phospho [Y43]
RBM22
Pre-mRNA-splicing factor RBM22
Phospho [Y116]
Epithelial discoidin domain-containing Phospho [Y792;
DDR1
receptor 1
Y796]
IPO9
Importin-9
Phospho [Y889]
FIGNL1
Fidgetin-like protein 1
Phospho [Y43]
ADGRD1
Adhesion G-protein coupled receptor D1 Phospho [Y125]
MTPN
Myotrophin
Phospho [Y21]
MARVELD2 MARVEL domain-containing protein 2
Phospho [Y377]
OFD1
Oral-facial-digital syndrome 1 protein
Phospho [Y558]
Phospho
NF1
Neurofibromin
[Y2577]
AKAP11
A-kinase anchor protein 11
Phospho [Y485]
LMCD1
LIM and cysteine-rich domains protein 1 Phospho [Y241]
Zinc finger CCCH domain-containing
ZC3H14
Phospho [Y321]
protein 14
Zinc finger CCCH domain-containing Phospho [Y499;
ZC3H7A
protein 7A
Y893]
PARP14

Poly [ADP-ribose] polymerase 14
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Table 3.2. List of proteins phosphorylated in MCF7-BD cells expressing SYK-EGFP when treated
with PV.
Accession
O60716
Q99569
Q8TEW0
Q14247
Q05655
Q13480
Q15464
Q9UIQ6

Gene Name
CTNND1
PKP4
PARD3
CTTN
PRKCD
GAB1
SHB
LNPEP

I3L4C2

BAIAP2

Q9Y446
Q12929
Q06124
Q9HCD6
Q99704
P56945
Q99747
Q96QD8

PKP3
EPS8
PTPN11
TANC2
DOK1
BCAR1
NAPG
SLC38A2

O15357

INPPL1

Q9BYG5
Q09666
Q13017

PARD6B
AHNAK
ARHGAP5

Q5VTI5

PLEKHA6

Q96A22
Q99952
Q8IZP0
P08727
P52943
Q99426
P15924
Q14011
A7KAX9
Q13561
Q7KZF4

C11orf52
PTPN18
ABI1
KRT19
CRIP2
TBCB
DSP
CIRBP
ARHGAP32
DCTN2
SND1

Description
Catenin delta-1
Plakophilin-4
Partitioning defective 3 homolog
Src substrate cortactin
Protein kinase C delta type
GRB2-associated-binding protein 1
SH2 domain-containing adapter protein B
Leucyl-cystinyl aminopeptidase
Brain-specific angiogenesis inhibitor 1-associated
protein 2
Plakophilin-3
Epidermal growth factor receptor kinase substrate 8
Tyrosine-protein phosphatase non-receptor type 11
Protein TANC2
Docking protein 1
Breast cancer anti-estrogen resistance protein 1
Gamma-soluble NSF attachment protein
Sodium-coupled neutral amino acid transporter 2
Phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase
2
Partitioning defective 6 homolog beta
Neuroblast differentiation-associated protein AHNAK
Rho GTPase-activating protein 5
Pleckstrin homology domain-containing family A
member 6
Uncharacterized protein C11orf52
Tyrosine-protein phosphatase non-receptor type 18
Abl interactor 1
Keratin, type I cytoskeletal 19
Cysteine-rich protein 2
Tubulin-folding cofactor B
Desmoplakin
Cold-inducible RNA-binding protein
Rho GTPase-activating protein 32
Dynactin subunit 2 OS=Homo sapiens
Staphylococcal nuclease domain-containing protein 1
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Table 3.2 continued
P21860
Q86X29
Q9UPX8
Q86UK7
Q9Y2X7
Q9C0H5
A0A0C4DFS6
O00151
P55072
G5E933

ERBB3
LSR
SHANK2
ZNF598
GIT1
ARHGAP39
SPRY4
PDLIM1
VCP
SBF1

Q9UEU0

VTI1B

Q9UDY2
Q9Y450
P49023
Q9P2M7
Q9HCU4
O75976
Q15223

TJP2
HBS1L
PXN
CGN
CELSR2
CPD
PVRL1

G3V1L9

TJP1

Q9HAU0

PLEKHA5

Q96PK6
Q9NZZ3
F8VQD4
Q14126
Q9C0C2
J3KNL6
Q86UE4
Q63HQ0
A0A0G2JPP5
Q8WV41
J3KN01
J3QRU1
P38159
P11274
Q8TAA9

RBM14
CHMP5
C12orf75
DSG2
TNKS1BP1
SEC16A
MTDH
AP1AR
SCRIB
SNX33
MLLT4
YES1
RBMX
BCR
VANGL1

Receptor tyrosine-protein kinase erbB-3
Lipolysis-stimulated lipoprotein receptor
SH3 and multiple ankyrin repeat domains protein 2
Zinc finger protein 598 OS=Homo sapiens
ARF GTPase-activating protein GIT1
Rho GTPase-activating protein 39
Protein sprouty homolog 4
PDZ and LIM domain protein 1
Transitional endoplasmic reticulum ATPase
Myotubularin-related protein 5
Vesicle transport through interaction with t-SNAREs
homolog 1B
Tight junction protein ZO-2
HBS1-like protein
Paxillin
Cingulin
Cadherin EGF LAG seven-pass G-type receptor 2
Carboxypeptidase D
Nectin-1
Tight junction protein 1 (Zona occludens 1), isoform
CRA_a
Pleckstrin homology domain-containing family A
member 5
RNA-binding protein 14
Charged multivesicular body protein 5
Overexpressed in colon carcinoma 1 protein (Fragment)
Desmoglein-2
182 kDa tankyrase-1-binding protein
Protein transport protein Sec16A
Protein LYRIC
AP-1 complex-associated regulatory protein
Protein scribble homolog
Sorting nexin-33
Afadin
Tyrosine-protein kinase
RNA-binding motif protein, X chromosome
Breakpoint cluster region protein
Vang-like protein 1
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Table 3.2 continued
Q8NFH5
P27361
Q5T0Z8
Q9BWF3
Q9GZY8

NUP35
MAPK3
C6orf132
RBM4
MFF

Nucleoporin NUP53
Mitogen-activated protein kinase 3
Uncharacterized protein C6orf132
RNA-binding protein 4
Mitochondrial fission factor
1-phosphatidylinositol 4,5-bisphosphate
P16885
PLCG2
phosphodiesterase gamma-2
P54760
EPHB4
Ephrin type-B receptor 4
O95297
MPZL1
Myelin protein zero-like protein 1
Q14161
GIT2
ARF GTPase-activating protein GIT2
Q9UPY3
DICER1
Endoribonuclease Dicer
O95684
FGFR1OP
FGFR1 oncogene partner
Q5VV41
ARHGEF16
Rho guanine nucleotide exchange factor 16
Q68DU7
DKFZp781C0425 BET1 homolog
Q9NZ63
C9orf78
Uncharacterized protein C9orf78
O76039
CDKL5
Cyclin-dependent kinase-like 5
O15231
ZNF185
Zinc finger protein 185
Q5T9C2
FAM102A
Protein FAM102A
Q12846
STX4
Syntaxin-4
P35568
IRS1
Insulin receptor substrate 1
Q9BU68
PRR15L
Proline-rich protein 15-like protein
Discs, large homolog 3 (Neuroendocrine-dlg,
Q5JUW8
DLG3
Drosophila), isoform CRA_b
Q9ULC8
ZDHHC8
Probable palmitoyltransferase ZDHHC8
Q7Z422
SZRD1
SUZ domain-containing protein 1
Q13405
MRPL49
39S ribosomal protein L49, mitochondrial
A0A087WWK8 IQSEC1
IQ motif and SEC7 domain-containing protein 1
O00221
NFKBIE
NF-kappa-B inhibitor epsilon
O60493
SNX3
Sorting nexin-3
Q9UQC2
GAB2
GRB2-associated-binding protein 2
Q14680
MELK
Maternal embryonic leucine zipper kinase
Q96IZ0
PAWR
PRKC apoptosis WT1 regulator protein
Q8N9U0
TC2N
Tandem C2 domains nuclear protein
P28482
MAPK1
Mitogen-activated protein kinase 1
Q68DH5
LMBRD2
LMBR1 domain-containing protein 2
Q5T5P2
KIAA1217
Sickle tail protein homolog
Q9NXD2
MTM410
Myotubularin-related protein 10
Q15654
TRIP6
Thyroid receptor-interacting protein 6
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Table 3.2 continued
Q6IA17
Q68D51
O15440
O75533
Q96RT1
Q9ULJ7

SIGIRR
DENND2C
ABCC5
SF3B1
ERBB2IP
ANKRD50

P19174

PLCG1

O15049
B7Z6Z4
Q8N8Z6
Q9UIW2
Q13151

N4BP3
MYL6
DCBLD1
PLXNA1
HNRNPA0

Q13443

ADAM9

Q9BY89
Q9H792
Q9HBL0

KIAA1671
PEAK1
TNS1

F8W9S7

PAGVD1

A0A087X165
Q7KZI7
P49840
B7ZKQ9
Q8N6H7
P11171

SRCIN1
MARK2
GSK3A
SCARB1
ARFGAP2
EPB41

Q13627

DYRK1A

E7EMB3
Q96NY8

CALM2
PVRL4

O94898

LRIG2

Q86XL3
A0A087WT05
Q5T9A4

ANKLE2
PCDHGA4
ATAD3B

C9JG63

SPRED2

Q15678

PTPN14

Single Ig IL-1-related receptor
DENN domain-containing protein 2C
Multidrug resistance-associated protein 5
Splicing factor 3B subunit 1
Protein LAP2
Ankyrin repeat domain-containing protein 50
1-phosphatidylinositol 4,5-bisphosphate
phosphodiesterase gamma-1
NEDD4-binding protein 3
Myosin light polypeptide 6
Discoidin, CUB and LCCL domain-containing protein 1
Plexin-A1
Heterogeneous nuclear ribonucleoprotein A0
Disintegrin and metalloproteinase domain-containing
protein 9
Uncharacterized protein KIAA1671
Pseudopodium-enriched atypical kinase 1
Tensin-1
GTPase-activating protein and VPS9 domain-containing
protein 1
SRC kinase-signaling inhibitor 1
Serine/threonine-protein kinase MARK2
Glycogen synthase kinase-3 alpha
SCARB1 protein
ADP-ribosylation factor GTPase-activating protein 2
Protein 4.1
Dual specificity tyrosine-phosphorylation-regulated
kinase 1A
Calmodulin
Nectin-4
Leucine-rich repeats and immunoglobulin-like domains
protein 2
Ankyrin repeat and LEM domain-containing protein 2
Protocadherin gamma-A4
ATPase family AAA domain-containing protein 3B
Sprouty-related, EVH1 domain-containing protein 2
(Fragment)
Tyrosine-protein phosphatase non-receptor type 14
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Q14241
Q8WX93
O15551
Q9H6X4
Q9H329
Q5W0Z9
Q9ULM3
O60437
P62191
Q96JQ2
R4GN18
Q8NI35
Q92982
A0A0C4DFY5
Q9Y2X9
Q13796

TCEB3
PALLD
CLDN3
TMEM134
EPB41L4B
ZDHHC20
YEATS2
PPL
PSMC1
CLMN
CD46
INADL
NINJ1
GPRC5C
ZNF281
SHROOM2

A0A0A0MTI2

SH2B2

Q9BRP8
Q86YV5
O00186
H3BNU0
P26006
Q99959
Q96HA1
G3V4K3
Q9NZV1
Q5T8I3

WIBG
SGK223
STXBP3
PRICKLE2
ITGA3
PKP2
POM121
VIPAS39
CRIM1
FAM102B

Q58DX5

NAALADL2

Q8IWW6

ARHGAP12

Q5SXH7

PLEKHS1

P46976
Q969Q0
Q969M3

GYG1
RPL36AL
YIPF5

Transcription elongation factor B polypeptide 3
Palladin OS=Homo sapiens
Claudin-3
Transmembrane protein 134
Band 4.1-like protein 4B
Probable palmitoyltransferase ZDHHC20
YEATS domain-containing protein 2
Periplakin
26S protease regulatory subunit 4
Calmin
Membrane cofactor protein (Fragment)
InaD-like protein
Ninjurin-1
G-protein-coupled receptor family C group 5 member C
Zinc finger protein 281
Protein Shroom2
Adaptor protein with pleckstrin homology and src
homology 2 domains, isoform CRA_a
Partner of Y14 and mago
Tyrosine-protein kinase SgK223
Syntaxin-binding protein 3
Prickle-like protein 2
Integrin alpha-3
Plakophilin-2
Nuclear envelope pore membrane protein POM 121
Spermatogenesis-defective protein 39 homolog
Cysteine-rich motor neuron 1 protein
Protein FAM102B
Inactive N-acetylated-alpha-linked acidic dipeptidaselike protein 2
Rho GTPase-activating protein 12
Pleckstrin homology domain-containing family S
member 1
Glycogenin-1
60S ribosomal protein L36a-like
Protein YIPF5
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P54284

CACNB3

Q04721
Q96DR7

NOTCH2
ARHGEF26

Voltage-dependent L-type calcium channel subunit beta3
Neurogenic locus notch homolog protein 2
Rho guanine nucleotide exchange factor 26

3.2.2.3.2 Treatment of cells with SA results in a unique SYK-dependent phosphorylation profile
Interestingly, there was a remarkable difference between the two treatment conditions in
the identities and nature of the substrates phosphorylated. This is consistent with the different
subcellular localizations of the kinase and its substrates in cells treated with PV versus SA. This is
illustrated in Figure 3.9 in which the overlap in identified phosphoproteins between the two
treatments is displayed. Based on a GO term analysis of the identified phosphoproteins (Table 3.4),
treatment with PV resulted in the phosphorylation of many proteins involved in cell-cell and cellsubstrate adhesion. This is consistent with the prominent staining of proteins near the cell periphery
with anti-phosphotyrosine in PV-treated cells. These substrates were largely absent from the list
of proteins phosphorylated in response to SA. In contrast, treatment with SA resulted in the
phosphorylation of many proteins involved in mRNA processing. Most of these were not observed
to be phosphorylated in cells treated with PV (Table 3.3).
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Figure 3.9. Venn diagram showing number of unique vs. duplicate phosphoproteins identified by
MS from cells treated with PV or SA.
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Table 3.3. GO term analysis of proteins phosphorylated in a SA- and SYK-dependent manner.
GO Biological Process
P-value
nuclear import (GO:0051170)
2.84E-04
protein import into nucleus (GO:0006606)
1.95E-02
protein targeting to nucleus (GO:0044744)
1.95E-02
single-organism nuclear import (GO:1902593)
2.28E-02
nucleocytoplasmic transport (GO:0006913)
1.20E-03
nuclear transport (GO:0051169)
1.57E-03
mRNA splicing, via spliceosome (GO:0000398)
9.41E-03
RNA splicing, via transesterification reactions with bulged adenosine as 9.41E-03
nucleophile (GO:0000377)
RNA splicing, via transesterification reactions (GO:0000375)
1.03E-02
mRNA processing (GO:0006397)
2.19E-03
RNA splicing (GO:0008380)
2.45E-02
mRNA metabolic process (GO:0016071)
1.95E-05
RNA processing (GO:0006396)
6.24E-03
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Table 3.4. GO term analysis of phosphoproteins from cells treated with PV.
GO Biological Process
desmosome organization (GO:0002934)
Bergmann glial cell differentiation (GO:0060020)
protein localization to cell junction (GO:1902414)
GDP metabolic process (GO:0046710)
cell-cell junction assembly (GO:0007043)
ERBB signaling pathway (GO:0038127)
epidermal growth factor receptor signaling pathway (GO:0007173)
adherens junction organization (GO:0034332)
cell-cell junction organization (GO:0045216)
cell junction organization (GO:0034330)
cell junction assembly (GO:0034329)
peptidyl-tyrosine phosphorylation (GO:0018108)
peptidyl-tyrosine modification (GO:0018212)
protein autophosphorylation (GO:0046777)
single organism cell adhesion (GO:0098602)
transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169)
single organismal cell-cell adhesion (GO:0016337)
enzyme linked receptor protein signaling pathway (GO:0007167)
response to lipopolysaccharide (GO:0032496)
cell morphogenesis involved in differentiation (GO:0000904)
cell-cell adhesion (GO:0098609)
biological adhesion (GO:0022610)
cell adhesion (GO:0007155)
cell morphogenesis (GO:0000902)
actin cytoskeleton organization (GO:0030036)
cellular component morphogenesis (GO:0032989)
actin filament-based process (GO:0030029)
cell morphogenesis involved in neuron differentiation (GO:0048667)
cell part morphogenesis (GO:0032990)
neuron projection morphogenesis (GO:0048812)
cell projection morphogenesis (GO:0048858)
positive regulation of GTPase activity (GO:0043547)
regulation of GTPase activity (GO:0043087)
regulation of cellular component movement (GO:0051270)
regulation of cell motility (GO:2000145)
regulation of cellular localization (GO:0060341)
cytoskeleton organization (GO:0007010)
positive regulation of catalytic activity (GO:0043085)

P-value
2.05E-04
5.42E-03
3.28E-04
4.89E-02
7.58E-06
1.55E-05
4.73E-03
1.35E-03
2.47E-11
2.12E-11
7.36E-07
6.06E-04
6.76E-04
6.76E-04
4.89E-05
1.31E-10
3.99E-02
2.55E-11
4.87E-02
4.26E-05
8.61E-04
9.96E-10
4.66E-09
1.30E-05
1.42E-02
6.69E-06
4.13E-03
4.58E-02
1.36E-02
2.94E-02
3.65E-02
3.53E-03
1.29E-02
4.70E-03
1.72E-02
1.24E-02
2.36E-02
1.33E-04
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Table 3.4 continued

single-organism organelle organization (GO:1902589)
anatomical structure morphogenesis (GO:0009653)
cell surface receptor signaling pathway (GO:0007166)
positive regulation of molecular function (GO:0044093)
protein localization (GO:0008104)
nervous system development (GO:0007399)
regulation of localization (GO:0032879)
vesicle-mediated transport (GO:0016192)
regulation of catalytic activity (GO:0050790)
cellular component assembly (GO:0022607)
regulation of molecular function (GO:0065009)
macromolecule localization (GO:0033036)
cellular component organization (GO:0016043)
regulation of signal transduction (GO:0009966)
cellular component organization or biogenesis (GO:0071840)
regulation of signaling (GO:0023051)
system development (GO:0048731)
cellular developmental process (GO:0048869)
single-organism developmental process (GO:0044767)
cell differentiation (GO:0030154)
anatomical structure development (GO:0048856)
developmental process (GO:0032502)
multicellular organism development (GO:0007275)
single organism signaling (GO:0044700)
signaling (GO:0023052)
cell communication (GO:0007154)
single-multicellular organism process (GO:0044707)
signal transduction (GO:0007165)
multicellular organismal process (GO:0032501)
single-organism cellular process (GO:0044763)
regulation of cellular process (GO:0050794)
regulation of biological process (GO:0050789)
biological regulation (GO:0065007)
single-organism process (GO:0044699)

6.59E-03
2.37E-05
8.66E-06
2.92E-04
4.04E-03
7.51E-04
1.35E-04
3.87E-02
3.48E-03
1.55E-02
2.50E-04
4.37E-02
1.68E-10
1.74E-02
1.99E-09
1.46E-02
3.18E-04
8.77E-03
2.10E-06
2.51E-02
2.12E-05
4.64E-06
2.77E-04
7.51E-05
7.78E-05
6.25E-05
7.05E-05
1.58E-02
4.34E-03
4.86E-03
5.03E-03
3.80E-03
2.67E-03
4.12E-04
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These results demonstrate that the treatment of cells with SA, which induces SG formation,
correlates with an extensive redistribution of SYK to substrates not observed in cells treated with
PV. Many of these SA-specific substrates are known to reside in cytoplasmic RNP granules
classified as either SGs or processing bodies (P-bodies). P-bodies also form in cells treated with
SA and contain many proteins in common with SGs.37 Table 3.5 shows a list of known SG and/or
P-body components identified as being phosphorylated in a SYK-dependent manner selectively in
SA-treated cells.38 These results are consistent with a prominent relocalization of SYK to RNP
granules in response to SA in MCF7 cells.

Table 3.5. List of SG and P-body components phosphorylated in a SYK-dependent manner.
Accession
Q99700
Q9UIV1
Q05048
Q8IU60
O95786
P26196
O43143
Q9UPY3
P57678
Q9NWZ8
Q86V48
Q96IZ0
Q92973
P50552
Q96JH7
P54577
Q6PJT7
Q8IWR0

Gene Name
ATXN2
CNOT7
CSTF1
DCP2
DDX58
DDX6
DHX15
DICER1
GEMIN4
GEMIN8
LUZP1
PAWR
TNPO1
VASP
VCPIP1
YARS
ZC3H14
ZC3H7A

Description
Ataxin-2
CCR4-NOT transcription complex subunit 7
Cleavage stimulation factor subunit 1
m7GpppN-mRNA hydrolase
Probable ATP-dependent RNA helicase DDX58
Probable ATP-dependent RNA helicase DDX6
Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15
Endoribonuclease Dicer
Gem-associated protein 4
Gem-associated protein 8
Leucine zipper protein 1
PRKC apoptosis WT1 regulator protein
Transportin-1
Vasodilator-stimulated phosphoprotein
Deubiquitinating protein VCIP135
Tyrosine-tRNA ligase, cytoplasmic
Zinc finger CCCH domain-containing protein 14
Zinc finger CCCH domain-containing protein 7A
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3.2.3

Dimerized SYK Signals through NFAT or NFκB when Interacting with the BCR
After demonstrating that the TMP dimer effectively dimerizes SYK when present within a

macromolecular complex, I sought to use it in a B cell system to determine the effects of SYK
dimerization on BCR signaling. To determine if Myc-SYK-eDHFR could support BCR signaling,
I expressed the protein in SYK-deficient DT40 cells and employed luciferase reporter assays for
two transcription factors that are activated downstream of BCR signaling: NFAT and NFκB. MycSYK-eDHFR was able to propagate signals from the BCR to both transcription factors. MyceDHFR, which was used as a control, was inactive as expected (Figure 3.10).
I explored the effects of induced SYK dimerization on BCR signaling by altering the extent
to which the SYK containing complexes were clustered by treating cells with anti-IgM to crosslink
the BCR and titrating in different amounts of TMP dimer. Interestingly, titration of higher
concentrations of TMP dimer resulted in significantly increased NFAT-luciferase activity induced
by anti-IgM (Figure 3.10A.). However, addition of the dimerizer had no significant effect on BCRstimulated NFκB activity (Figure 3.10B.).
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Figure 3.10. The TMP dimer enhances BCR-dependent activation of NFAT, but not NFκB. A.
SYK-deficient DT40 cells transiently transfected with an NFAT-driven luciferase reporter plasmid
and with plasmids for the expression of either Myc-eDHFR or Myc-SYK-eDHFR were activated
by receptor crosslinking with anti-IgM where indicated in the presence of increasing
concentrations of TMP dimer (TMPd). Values were normalized to 1 for cells activated with antiIgM in the absence of TMPd. Values represent means +/- SEM of triplicate assays repeated three
times. ** P < 0.01. B. SYK-deficient DT40 cells were transfected and treated as in panel a, except
that an NFκB-driven luciferase reporter plasmid was used. ns, not significant. The expression of
Myc-SYK-eDHFR was verified by Western blotting with antibodies against SYK. GAPDH was
detected as a loading control.
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3.2.4

TMP Dimer-induced SYK Activation Requires Association with the BCR
Previous research has demonstrated that dimerization of SYK by fusion with a dimerization

domain derived from TEL results in constitutive kinase activity due to autophosphorylation. 39, 40
Therefore, as controls, I asked if the dimerization of Myc-SYK-eDHFR alone was sufficient to
trigger signaling through NFAT or NFκB in the absence of BCR crosslinking. At the highest
concentration of TMP dimer tested (10 M), neither transcription factor was activated (Figure 3.10.
A and B). I then asked if SYK-eDHFR could transmit signals following dimerization if it was first
targeted to the plasma membrane. I expressed in cells a form of SYK-eDHFR fused to a
membrane-targeting sequence consisting of the first five amino acids derived from the N-terminus
of LYN (NLyn, Figure 3.11). As shown by immunofluorescence of transiently transfected DT40
cells, NLyn-SYK-eDHFR was membrane-bound, while Myc-SYK-eDHFR was expressed
throughout the cell (Figure 3.12). However, while NLyn-SYK-eDHFR was capable of supporting
signaling through the BCR, dimerization alone was still insufficient to propagate a measurable
signal (Figure 3.13. A and B). I cannot rule out an activation of SYK-eDHFR fusion proteins
through dimerization as is seen with TEL-SYK fusion proteins. However, the TMP dimer does not
activate the SYK-fusion protein independent of its interaction with the BCR in a manner that leads
to the activation of either NFAT or NFκB.
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Figure 3.11. The LYN N-terminal (NLyn) sequence. LYN is cotranslationally N-myristoylated
and subsequently S-palmitoylated to target the protein to the plasma membrane.41
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Figure 3.12. NLyn-tagged SYK is localized to the plasma membrane. SYK-deficient DT40 cells
were transiently transfected to express NLyn-SYK-eDHFR or Myc-SYK-eDHFR. Cells were
fixed and stained with antibodies against SYK. Nuclei were stained with DAPI. The expression of
each protein was verified by Western blotting.
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Figure 3.13. Dimerization of membrane-associated SYK is not sufficient to activate transcription
factors. SYK-deficient DT40 cells were transiently transfected with plasmids coding for NLynSYK-eDHFR and luciferase reporter plasmids for detecting the activation of either NFAT (A) or
NFκB (B). Cells were treated with anti-IgM antibodies to crosslink the BCR or with increasing
concentrations of TMP dimer (TMPd). The expression of NLyn-SYK-eDHFR was verified by
Western blotting with antibodies against SYK. Data represent the means +/- SEM of triplicate
experiments repeated three times.
I also performed the same assays with cells expressing SYK lacking the eDHFR affinity
tag, but containing a different C-terminal tag: EGFP. While cells expressing SYK-EGFP could
signal through the BCR to the activation of NFAT, the TMP dimer had no effect on signaling
(Figure 3.14). Thus, the eDHFR TMP-binding domain was required for dimer-enhanced signaling.
As an additional control, I added a ten-fold excess of free TMP two hours after the addition of
anti-IgM and TMP dimer to DT40 cells expressing Myc-SYK-eDHFR. Free TMP significantly
reduced the dimer-induced increase in NFAT-luciferase activity (Figure 3.15). These results
indicate that the observed increase in NFAT activity was due to binding of the TMP dimer to
eDHFR-tagged SYK.
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Figure 3.14. Enhanced NFAT activation by the TMP dimer requires the eDHFR affinity tag. SYKdeficient DT40 cells transiently transfected with an NFAT-driven luciferase reporter plasmid and
with a plasmid for the expression of SYK-EGFP were activated by receptor crosslinking with antiIgM where indicated in the presence of increasing concentrations of TMP dimer (TMPd). Values
represent means +/- SEM of triplicate assays repeated three times. The expression of SYK-EGFP
was verified by Western blotting.
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Figure 3.15. Enhanced NFAT activation requires binding of TMP dimer to eDHFR-tagged SYK.
SYK-deficient DT40 cells transiently transfected with an NFAT-driven luciferase reporter plasmid
and with a plasmid for the expression of Myc-SYK-eDHFR were activated by receptor
crosslinking with anti-IgM in the presence of 10 mM TMP dimer (TMPd). Where indicated, an
excess of TMP (100 mM) was added 2 h following activation. Values represent means +/- SEM
of triplicate assays repeated three times. ** P < 0.01. The expression of Myc-SYK-eDHFR was
verified by Western blotting.
3.2.5

Dimerization of SYK Promotes Sustained Ca2+ Mobilization
While NFAT and NFκB are both activated by Ca2+ signaling downstream of BCR

crosslinking, they are differentially regulated by its duration and amplitude. Large, brief pulses of
Ca2+ activate NFκB, while low, sustained Ca2+ mobilization is needed to activate NFAT.42 To
determine the effect of SYK dimerization on Ca2+ mobilization, I measured intracellular Ca2+
levels in SYK-deficient DT40 B cells stably expressing Myc-SYK-eDHFR. Cells were loaded
with the Ca2+-binding dye Fluo-4 and activated with or without the TMP dimer. Addition of the
TMP dimer resulted in a more sustained mobilization of intracellular Ca2+ (Figure 3.16), an effect
that is consistent with the enhanced NFAT activity.
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Figure 3.16. The TMP dimer enhances the duration of calcium mobilization. SYK-deficient DT40
cells stably expressing Myc-SYK-eDHFR and labeled with Fluo-4 were activated by anti-IgM in
the absence or presence of the TMP dimer (TMPd). Fluorescence readings were obtained every 5
sec. Data represent means +/- SEM of triplicate experiments repeated three times.
3.2.6

Retention of the BCR at the Plasma Membrane Enhances Signaling through NFAT
I hypothesized that the prolonged calcium mobilization resulted from a SYK- and dimer-

promoted retention of the BCR complex at the plasma membrane. To examine this, I treated DT40
cells stably expressing Myc-SYK-eDHFR with Texas Red-labeled goat anti-chicken IgM for
various amounts of time, with or without TMP dimer. I then stained the cells for SYK and analyzed
the images for colocalization of the kinase with the BCR at the plasma membrane. Examples are
shown in Figure 3.17.A. As determined by increased Pearson correlation coefficients, cells treated
with the TMP dimer exhibited a larger and more persistent degree of colocalization of SYK with
the membrane-bound BCR complex (Figure 3.17.B).
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Figure 3.17. The TMP dimer increases the retention of SYK-BCR complexes. A. DT40 cells
stably expressing Myc-SYK-eDHFR were treated with Texas Red-labeled anti-IgM (red) with or
without TMP dimer for the indicated time points, then fixed, permeabilized and stained with
antibodies against SYK (blue). B. Images were analyzed by ImageJ for colocalization of anti-IgM
and SYK.
To further support a role for BCR retention at the membrane in signaling, I inhibited its
internalization by promoting actin depolymerization using Latrunculin B (LatB).25 The treatment
of DT40 cells expressing Myc-SYK-eDHFR with LatB resulted in a substantial increase in antiIgM-induced NFAT activity (Figure 3.18). Consistent with a previous report,22 I found that
treatment with the actin depolymerizing agent alone enhanced signaling from the unligated BCR
(Figure 3.18). This effect was enhanced when the BCR also was crosslinked with anti-IgM.
Interestingly, the addition of the TMP dimer also enhanced signaling induced by LatB in the
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absence of anti-IgM. These data are consistent with a correlation between an enhanced retention
of the BCR complex at the plasma membrane and increased signaling through NFAT.

Figure 3.18. Retention of BCR complex at the plasma membrane enhances NFAT signaling. SYKdeficient DT40 cells transiently transfected with an NFAT-driven luciferase reporter plasmid and
with a plasmid for the expression of Myc-SYK-eDHFR were activated by receptor crosslinking
with anti-IgM in the absence or presence of LatB. Values represent means +/- SEM of triplicate
assays repeated three times. ** P < 0.01.
3.3

Discussion

Several systems have been described for chemically inducing the dimerization of proteins
in cells to explore signaling pathways.43 The first of these utilized a synthetic dimer of FK506
(KF1012) to crosslink a chimeric protein consisting of a myristoylated TCR ζ chain fused to
FKBP12 to study TCR signaling.44 I extended this approach to the development of a methodology
for examining the role of SYK and the induced formation of SYK-SYK complexes in BCRmediated signaling through the generation of a SYK-eDHFR fusion protein and the preparation of
a synthetic dimer of TMP. Previous work had shown that eDHFR can be dimerized by a synthetic
dimer of methotrexate.45 For these studies, I generated a dimer of TMP rather than methotrexate
since TMP is a specific ligand for the bacterial form of DHFR that is bound with greater than
10,000-fold higher affinity by eDHFR as compared to mammalian DHFR.46
Fusion proteins containing the eDHFR-tag retain the ability to bind TMP and can be
clustered by addition of the TMP dimer as shown by an increase in the size of SGs, which are
particles that bind SYK28 and have liquid-like properties that allow them to fuse to form larger
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droplets.34 This phenomenon combined with phosphoproteomic data confirm the physical
presence of SYK in SGs. I demonstrate that SG-inducing conditions promote SYK redistribution
from the detergent-soluble fraction to the detergent-insoluble fraction, consistent with its
localization to SGs. This redistribution results in a unique phosphorylation profile compared to
conditions that promote SYK-dependent tyrosine phosphorylation but do not induce SG formation.
Phosphoproteomic analyses of SA- and SYK-dependent tyrosine phosphorylation identified a
number of components of SGs and P-bodies, giving us a clue as to how SYK functions within
these granules. These analyses additionally suggest a role for SYK in P-bodies as well as SGs
based on the identification of multiple P-body components as substrates. Recent follow up studies
in our laboratory have since confirmed a physical association of SYK with P-bodies. The
identification of SG and P-body components that serve as substrates should establish the
groundwork for future experiments to examine the effects of SYK-dependent phosphorylation on
SG and P-body functions.
I find that the induced dimerization of receptor-associated SYK (expressed as Myc-SYKeDHFR) results in an increased and prolonged existence of kinase-BCR complexes at the plasma
membrane. It is clear from studies on antigens and anti-receptor antibodies of different solubilities
and valencies that extensive clustering of the BCR complex, or of BCR microclusters, promotes
robust signaling.7-11, 13, 14, 19, 20 A critical component of the signal initiation process is the creation
of binding sites on the receptor for SYK. BCR engagement also results in receptor internalization,
but it is the liganded BCR complexes that remain at the plasma membrane that represent the units
that are actively signaling.47 Initial phosphorylation of the first tyrosine of the BCR ITAMs is
thought to be catalyzed by LYN.2 However, continued receptor phosphorylation catalyzed by SYK
is needed to maintain active BCR complexes at the membrane. Since BCR internalization requires
an unphosphorylated tyrosine residue within the ITAM of CD79B,48 it is likely that continued
ITAM phosphorylation by receptor-associated SYK is important for receptor retention at the
plasma membrane. Thus, it is likely that the effect of the TMP dimer on signaling in cells
expressing Myc-SYK-eDHFR is a consequence of enhanced interactions of neighboring kinasereceptor complexes, leading to their phosphorylation and retention at the plasma membrane.
A role for receptor retention at the membrane for enhancing BCR signaling is consistent
with the observation that inhibitors of actin polymerization, which inhibit receptor internalization,
also enhance BCR signaling.17, 22 It is interesting that actin depolymerization also can induce
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signaling from the BCR even in the absence of receptor crosslinking22 through the opening of BCR
receptor complexes that are normally restrained by actin.17 This actin depolymerization-induced
BCR signaling also is dependent on SYK,22 which is required to mediate opening of the BCR
oligomers via an inside-out mechanism.17 My data indicate that LatB-induced signaling is greatly
enhanced by increasing SYK-SYK interactions through kinase dimerization, consistent with a
requirement for SYK in mediating BCR signaling induced by actin depolymerization.
It is interesting that the induced dimerization of receptor-associated SYK affects the quality
of the signal sent from the clustered BCR complex. I observe a pronounced effect of kinase
dimerization on the receptor-mediated activation of NFAT, but no significant effect on the
activation of NFκB. SYK, activated at the site of clustered BCR complexes, catalyzes the
phosphorylation of the scaffolding protein BLNK/SLP-65. SYK also has been reported to
physically associate with BLNK such that a kinase-independent scaffolding function also
contributes to enhanced Ca2+ mobilization.49 This SYK-dependent phosphorylation of BLNK
promotes the assembly of signalosome complexes containing BTK and PLC. PLC, activated by
BTK, is essential for the generation of the second messengers diacylglycerol and inositol
trisphosphate needed for calcium mobilization and activation of both the NFAT and NFκB
pathways.50 The activation of NFκB occurs in response to high, but transient, increases in
intracellular calcium, while NFAT is activated in response to low, but sustained levels of
calcium.42 A selective activation of NFAT is consistent with our observed changes in the duration,
but not the amplitude of calcium responses that I see in cells that are treated with anti-IgM in the
presence of the TMP dimer. This prolonged maintenance of the calcium plateau in dimer-treated
cells is likely a consequence of the prolonged residency of kinase-BCR complexes at the
membrane. Thus, molecules and processes that regulate receptor clustering and internalization
from the interior of the cell have the capacity to modulate the quality of signals sent from the
antigen receptor. This is interesting as the physiological outcome of receptor occupancy, cellular
activation versus anergy, also is dependent on the quality of the signal, with prolonged receptor
occupancy and selective activation of NFAT being associated with anergic responses.51, 52
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FUTURE DIRECTIONS

4.1

Introduction

The utility of the TMP-eDHFR chemical biology system allows its use in multiple
applications. Already, the high affinity and selectivity of TMP for eDHFR has fostered the
development of many different chemical probes that bind eDHFR-tagged proteins in live cells. To
date, four classes of TMP probes have been developed: chemical inducers of heterodimerization
(CID),1-3 in vivo protein ligation,4 organic dyes for live cell imaging,5-9 and probes to manipulate
intracellular localization of eDHFR-tagged protein.10, 11
In this study, I have described the synthesis and use of two new TMP probes: TMP dimer
and immobilized TMP for the affinity capture of eDHFR-tagged protein. The TMP dimer I
synthesized is the first example of a TMP-based probe for inducing homodimerization.
Development of TMP affinity pull-down methods harbors great potential for future use in studying
protein-protein interactions.
Although the chemical probes I developed have proven effective, optimized molecules
with improved properties could be generated. Many additional approaches could also be
envisioned to take advantage of this chemical biology system by synthesizing new types of TMPbased probes. In the course of this study, I designed and/or synthesized several additional probes
that illustrate potential future applications of this technology.

4.2

Optimized TMP Dimer Synthesis

Although I demonstrated that the TMP dimer effectively induced aggregation of eDHFRtagged SYK, the most effective concentration tested (10 μm) was approximately 1000× higher
than the affinity constant (Kd = 9.1 nm).12 It is possible that the polarity of the linker reduced
cellular uptake of the dimer. If this were the case, low polarity, hydrophobic linkers could increase
cellular uptake and allow lower effective doses.
While multiple linker chemistries could potentially improve the molecule, I highlight two
possibilities. First, replacing the diethylenetriamine with a hydrocarbon such as 1,6hexanediamine would replace the polar secondary amine group with two carbons (Figure 4.1), thus
reducing the polarity.
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Figure 4.1. TMP dimer linked with 1,6-hexanediamine in place of diethylenetriamine.
Second, one could utilize coupling chemistry other than amide coupling. For instance, one
could synthesize an azide-substituted analog of TMP as shown in Figure 2.5 and perform Click
chemistry with a reagent such as 1,8-nonadiyne (Figure 4.2). This would replace the amides with
nonpolar triazole rings.

Figure 4.2. Click reaction with TMP analog 15 and 1,8-nonadiyne to generate a TMP dimer.
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4.3

TMP Pull-down Methods

Affinity purification of tagged proteins has become widely used in biological research,
resulting in the development of many different affinity purification systems.13, 14 These methods
differ considerably in final yield, purity, and cost.13 Interestingly, the methods yielding the highest
purity product require expensive, low capacity resins. Contrastingly, inexpensive methods with
high capacity resins tend to yield low purity products.13 The development of high yield, high purity,
low cost affinity resins would greatly benefit protein biology research.
The TMP-agarose beads I developed demonstrated great potential for utility in biological
research. For instance, I found that a small quantity of beads (5 μL) was sufficient to pull down
significant quantities of protein in only 5-15 min. Unfortunately, however, agarose beads have
been shown to bind many proteins non-specifically, as evidenced by “beadome” proteins that are
often detected in proteomic analyses.15,

16

This often limits their utility in protein-protein

interaction studies. Several modifications could improve this method.
4.3.1

Water-Soluble TMP for Protein Elution
One great advantage of several affinity pull-down methods is the ability to elute the protein

of interest by addition of a small molecule under mild conditions.13 The ability to elute eDHFRtagged proteins from TMP-agarose beads by addition of free TMP would allow specific elution of
the protein of interest and any associated proteins. Additionally, it would purify the protein of
interest without eluting contaminating “beadome” proteins. Unfortunately, however, TMP is
poorly water-soluble (~1 mg/mL at low pH). This necessitates modification of TMP with
hydrophilic groups to achieve aqueous concentrations sufficient to elute protein from the resin.
One option is the attachment of carbohydrates to TMP (Figure 4.3). As described in Figure 2.6,
after deprotecting the TMP 4’-methoxy moiety, I alkylated the phenol with an O-acetyl-protected
analog of glucose. I then deprotected the alcohols to yield a TMP-glucose derivative.

Figure 4.3. Chemical structure of glycated TMP.
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It is possible that more than one carbohydrate moiety may be needed to achieve high
aqueous concentrations (~100 mM). After optimization of this synthetic process, the TMP-agarose
beads can be used in a similar manner as other commercially available resins to purify eDHFRtagged proteins. The beads can be incubated with lysates from cells expressing eDHFR-tagged
protein, washed, and the protein eluted with free TMP.
4.3.2

Disulfide Linker for Protein Elution
A second possibility to selectively elute the protein of interest from TMP-agarose beads is

to employ disulfide chemistry. The addition of a disulfide bond in the linker connecting TMP to
the beads would allow selective cleavage by adding reducing agents such as dithiothreitol (DTT),
as shown in Figure 4.4.

Figure 4.4. Selective cleavage of TMP from agarose beads by reducing disulfide bond.
4.3.3

Magnetic Pull-down Beads
One disadvantage to using agarose or Sepharose beads is that cell debris or detergent-

insoluble complexes cannot be easily separated from the beads by centrifugation. In situations
where this cannot be avoided, magnetic beads have been proven effective.17 After incubation with
cell lysates containing particulate matter, magnetic beads are pulled to the side of the tube by a
magnet. The undesired solids are thus separated from the beads, allowing purification that would
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not be achievable with agarose or Sepharose beads.17 Optimization of manufacturing procedures
has also led to the development of smaller beads, to reduce sedimentation rate, with maximized
surface area to increase loading capacity.18 These beads can be loaded with antibodies or other
affinity molecules for immunoprecipitation and other pull-down techniques.17, 19-22
The development of TMP-coupled magnetic beads would extend the benefits of the TMP
affinity pull-down method to applications where agarose beads are not effective. For example,
TMP-coupled magnetic beads could be used to purify Myc-SYK-eDHFR associated with SGs and
P-bodies. This would allow pull-down of these macromolecular complexes that are poorly
detergent-soluble to more effectively study their components, and would greatly facilitate
proteomic and other analyses of similar complexes.
4.3.3.1 Stable Cell Selection
The effectiveness of magnetic pull-down methods has also been extended to the isolation
of intact cells.21, 22 This is accomplished directly by coating the beads with antibodies recognizing
extracellular antigen, or indirectly by incubating the cells with a primary antibody and coating the
beads with a secondary antibody.21 The desired cell type is then immunoprecipitated by applying
a magnet.
Beyond isolating specific cell types from complex mixtures such as blood,21 this method
can be applied to the selection of transfected cells stably expressing a protein of interest. 23
Currently, the most common method to select stable cell lines is the inclusion of a drug resistance
gene in the vector, so that cells expressing the gene of interest are resistant to the drug while others
are not. However, this requires optimization to determine the most effective drug dose for each
cell line, and selection often requires a significant amount of time. By developing a vector that
encodes the gene of interest and an extracellular antigen, it is possible to simply pull-down
transfected cells with magnetic beads to separate them from non-transfected cells.23
The development of a vector such as the one shown in Figure 4.5 would allow concurrent
expression of a gene of interest and eDHFR as an extracellular antigen. Cells could be transfected
with this vector, and then selected with TMP-coupled magnetic beads. Adherent cell lines would
need to be detached from culture dishes by methods other than trypsinization, such as Ca 2+
chelation. The detached cells would then be incubated with TMP-coupled magnetic beads, and a
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magnet applied to separate them. After extensive washing, the cells could be removed from the
beads by trypsin.

Figure 4.5. Hypothetical eDHFR pull-down vector. The vector contains a multiple cloning site
(MCS) for gene insertion and encodes eDHFR preceded by a signal peptide sequence (SPS) and
followed by a stop-transfer sequence (STS). Expression of the inserted gene is driven by the CMV
promoter, while eDHFR expression is driven by the SV-40 promoter.
4.4

TMP-Aryl Azide Fingerprint Assay

Protein-protein interactions are often transient, dynamic, and, in some cases, low affinity.
Additionally, in vitro methods to study proteins often utilize conditions that are not physiologically
relevant, and may not promote protein-protein interactions that would occur in live cells.24 These
are major challenges that new methods seek to overcome.
Aryl azides are reagents that can be photolyzed to form highly reactive nitrenes. The
nitrenes then bind covalently to nearby compounds or macromolecules via C-H or heteroatom-H
bond insertion.24 Additionally, aryl azides are stable in physiological conditions, making them
suitable reagents for the study of protein-protein interactions.25
In a biological context, aryl azides were first used to study antibody-antigen interactions.
Fleet and colleagues25 developed an antibody specific for the 4-azido-2-nitrophenyl group, and
demonstrated that photolysis covalently labeled the antibody.25 This has led to the development of
a variety of photoactivatable reagents that can be used to study protein-protein interactions.24, 26
However, the majority of commercially available reagents can only be used in vitro, and the few
that can be used in live cells are difficult to target to specific subcellular locations. The
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development of cell-permeable reagents that can be targeted to specific complexes would greatly
facilitate the study of protein-protein interactions.
TMP-based aryl azide probes show great potential for development of targeted
photoactivatable reagents that can be used in live cells. I synthesized two potential probes, as
shown in Figure 4.6. I utilized linkers of varying sizes to covalently couple TMP to 3-azidobenzoic
acid or 1-fluoro-2-nitro-4-azidobenzene. In this system, one would treat cells expressing an
eDHFR-tagged protein of interest with a TMP-aryl azide analog, allowing the TMP to bind the
eDHFR. The cells would be washed to remove excess probe, treated to form complexes, if needed,
and the probe would be photolyzed. By generating anti-TMP antibodies, one could then
immunoprecipitate any TMP-labeled proteins and analyze them biochemically or by MS.

Figure 4.6. Chemical structures of two TMP-aryl azide analogs.
As an example, these probes could be used with MCF7-BD cells stably expressing MycSYK-eDHFR. After incubating the cells with the probe and washing the cells, they could be treated
with SA to induce SG formation. Then the probe could be photolyzed to label proteins that
associate with SYK. The cells would then be lysed, and magnetic beads coated with anti-TMP
antibodies used to pull-down TMP-labeled proteins. These could then be analyzed by MS and/or
Western blotting, allowing identification of the “fingerprint” pattern SYK leaves when activated
by SA.
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4.5

Subcellular Translocation Assay

The ability of an enzyme to carry out its proper metabolic function within a cell is
dependent not only on its intrinsic catalytic activity, but also its subcellular location. The exquisite
control of enzymatic activity often involves the dynamic regulation of both of these properties.
The localization of signaling proteins such as G-proteins and kinases is essential for each to exert
the desired function.27-30 Transcription factors function in the nucleus to regulate gene expression,
and are often exported to the cytoplasm as a means of inactivation.31-36 However, to date it has
been very difficult to effectively study and manipulate protein localization. An approach to
selectively shuttle proteins to specific subcellular compartments would significantly enhance our
understanding of this phenomenon. It would also facilitate the study of protein function for many
different types of proteins.
Nature uses short peptide sequences to control protein localization. These sequences are
recognized by various proteins or complexes, and result in translocation to specific compartments.
Therefore, it seems highly plausible that tagging TMP with these peptide sequences would result
in translocation of eDHFR-tagged proteins. Under this logic, I used a peptide synthesizer to
synthesize nuclear localization (NLS) and nuclear export (NES) sequence peptides.

I also

synthesized a CaaX box plasma membrane-targeting peptide. I then added the TMP analog
containing the 5-carbon acid linker directly to the peptide synthesizer to covalently couple TMP
to these peptides. I incubated these compounds with HEK293T cells stably expressing SYKEGFP-eDHFR or EGFP-eDHFR and monitored the cells by fluorescence microscopy to visualize
protein translocation. However, no noticeable change in localization occurred.
Interestingly, Hashiro et al.10 used a similar approach to modulate protein localization in
live cells. They synthesized an AKT substrate peptide bound to TMP and a fluorescent marker.
They then expressed in cells a membrane-targeted eDHFR and AKT-GFP. However, they noted
that this compound was not cell permeable, and microinjection was required to visualize a change
in the localization of AKT-GFP.10 With this in mind, I had a fluorescein-labeled NLS peptide
custom synthesized to include a membrane-permeable sequence (9Arg). Unfortunately, the
membrane-permeable sequence was still insufficient to observe green fluorescence in HEK293T,
MCF7, or MDA-MB-231 cells.
Later Ishida et al.11 developed TMP analogs bound to small molecules that localize to
specific subcellular compartments. These included a myristoylated short peptide mimicking the
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LYN membrane localization sequence, the Hoechst DNA-binding dye, and the microtubulebinding drug taxol. They showed proof of concept validations, demonstrating translocation of
fluorescent proteins.11 However, to date this approach has not been used to study protein function.
Further research is needed to determine the effects of translocation on intracellular processes.
Previous studies in our laboratory have demonstrated that SYK localizes to and functions
in both the nucleus and cytoplasm.30 BCR engagement by antigen leads to translocation of SYK
from the nucleus, and SYK reenters the nucleus upon BCR internalization. Additionally, treating
cells with oxidative stress when SYK is excluded from the nucleus results in SYK-dependent
activation of caspase 3, while nuclear localization of SYK prevents caspase 3 activation.30 Future
studies should combine cells expressing Myc-SYK-eDHFR with TMP localization analogs to
further study this phenomenon. This would help us better understand the contributions of SYK to
cell survival and apoptosis.

4.6

Conclusion

The eDHFR-TMP chemical biology system is versatile in its applications due to various
factors. TMP is an inexpensive small molecular that can be easily modified without affecting its
affinity for eDHFR.37, 38 Additionally, eDHFR is a small protein (~18 kDa), making it an ideal
protein tag. The high affinity (Kd = 9.1 nm)12 and selectivity (TMP exhibits >10,000× higher
affinity for eDHFR than mammalian DHFR)39 of the eDHFR-TMP interaction render it useful for
many applications.
While a number of TMP analogs have been developed as chemical probes for biological
systems, development of new probes and optimization of existing probes would greatly benefit
chemical biology research. Optimization of TMP dimer linker chemistry would allow the use of
lower doses to study the effects of protein aggregation in live cells, and may facilitate use in animal
models. The development and optimization of TMP pull-down methods would greatly benefit the
study of protein-protein interactions. TMP-coupled magnetic beads could also be used to simplify
cell selection procedures. Finally, TMP-coupled aryl azides would allow dynamic study of
macromolecular complexes and the “fingerprints” of kinases or other components of these
complexes. I have provided detailed synthetic procedures for some of these probes. Future work
should focus on development of these products and discovering optimal conditions for their use in
biological systems.
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